Hashimoto's Thyroiditis
Hashimoto's thyroiditis is a chronic autoimmune disease and the leading cause of primary hypothyroidism, in which loss of immune tolerance to thyroid antigens (thyroid peroxidase and thyroglobulin) drives lymphocytic infiltration and progressive destruction of thyroid follicular cells. CD4 and CD8 T cells together with anti-TPO and anti-thyroglobulin autoantibodies deplete the gland, producing thyroid hormone deficiency that manifests as fatigue, weight gain, cold intolerance, and goiter. Susceptibility is conferred by HLA and other immune-regulatory loci interacting with environmental triggers such as iodine excess and viral infection, and levothyroxine replacement reverses the hypothyroid syndrome.
Ask OpenScientist
Ask a research question about Hashimoto's Thyroiditis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Submitting...
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Classifications
Harrison's Part
Comorbidities
Mechanistic Hypotheses
1Canonical Autoimmune Thyrocyte Destruction Model
Evidence balance
3 support
Hashimoto's thyroiditis is a chronic autoimmune disease in which loss of immune tolerance to thyroid antigens — primarily thyroid peroxidase (TPO) and thyroglobulin (Tg) — drives lymphocytic infiltration of the thyroid gland, formation of intrathyroidal tertiary lymphoid structures, and progressive thyrocyte destruction. CD4 Th1 and Th17 cells, CD8 cytotoxic T cells, and autoantibody-mediated effects (anti-TPO, anti-Tg) act together to deplete follicular cells, producing primary hypothyroidism. Susceptibility is conferred by HLA-DR3/DR5, CTLA4, PTPN22, and other immune-regulation loci, with environmental triggers including iodine excess, viral infection, and selenium deficiency. Levothyroxine replacement reverses the hypothyroid syndrome by bypassing the destroyed gland, supporting glandular failure as the proximate clinical lesion in this canonical model.
Retained as CANONICAL. The 2026 openscientist hypothesis-search report (kb/hypotheses/Hashimotos_Thyroiditis/canonical_autoimmune_thyrocyte_destruction_model) confirms 12 of 13 mechanistic claims as established. Core effector mechanisms — Fas/FasL-mediated thyrocyte apoptosis (sensitized by IFN-γ + IL-1β, independent of perforin/granzyme), intrathyroidal tertiary lymphoid structures functioning as germinal centers with RAG1/RAG2 in situ receptor revision, and coordinated CD4 Th1/Th17 + CD8 + autoantibody (anti-TPO in >90%) responses — are validated by histopathology, single-cell transcriptomics, and immune-checkpoint-inhibitor-induced thyroiditis as a natural experiment. JAK inhibition has provided proof-of-concept reversal. Six refinements: (1) Th17/Treg imbalance is now established as an upstream initiator preceding Th1-mediated destruction, not captured by the seed description; (2) IgG4-related thyroiditis (~27%) and seronegative HT (~12%) are clinically significant subtypes the model does not address; (3) GWAS identifies 418 independent signals (vs ~5 canonical loci) explaining only ~5.4% of variance, indicating extensive polygenicity; (4) the gut-thyroid axis (molecular mimicry, SCFA depletion) provides a mechanistic bridge from environmental triggers to immune dysregulation; (5) thyrocyte HLA class II expression (Bottazzo hypothesis) and NETosis are increasingly implicated; (6) sex-specific intrathyroidal B-cell homing via CXCL13-CXCR5 helps explain the female predominance. The initial tolerance-breaking event remains unknown and no disease-modifying RCT has yet been completed.
Deep research
Show evidence (3 references)
"Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
Canonical mechanism reference used as the seed for the hypothesis-search deep-research run. It supports the autoantibody plus lymphocytic-infiltration core of the model, but not the full CD4 Th1/Th17, CD8, tertiary-lymphoid-structure, or genetic-susceptibility claims in the hypothesis description.
"we performed a genome-wide association meta-analysis of 81,718 AIHT cases in FinnGen and the UK Biobank, identifying 418 independent signals"
Substantiates refinement (3) in the notes above, which until now was asserted only in prose. The susceptibility architecture behind this hypothesis is far more polygenic than the HLA-DR3/DR5, CTLA4 and PTPN22 loci the description names: 418 independent genome-wide significant signals in 81,718 cases. The same study reports coding variants in LAG3, ZAP70 and TG among the lead signals, which converges with the LAG3 variant already curated in this entry from an independent source.
"The variability explained by this model was assessed at only 5.4821%"
Quantifies how little of the predisposition the named canonical loci account for, supporting the same polygenicity refinement. Note the scope: this is a seven-variable model over candidate SNPs plus HLA-DRB1 sequencing in 147 cases and 147 controls in a single Polish cohort. It is not a variance-explained figure for the 418 GWAS signals above, and the openscientist report's juxtaposition of the two numbers should not be read that way.
Discussions and Knowledge Gaps
6What converts genetic susceptibility plus environmental exposure into the first breach of tolerance to thyroid peroxidase and thyroglobulin, and can that initiating event be observed before autoantibodies appear?
Every mechanism curated downstream of this node is comparatively well-evidenced, and the node itself is not. The entry wires four candidate routes into it, hyperiodinated thyroglobulin, selenoprotein-limited oxidative injury, weakened vitamin D-dependent immunoregulation, and hepatitis C-associated immune activation, and none of them is shown to be the initiating event rather than a contributing risk state. The 2026 openscientist hypothesis-search report reached the same conclusion after checking viral triggers including SARS-CoV-2, iodine excess, gut dysbiosis, epigenetic modification, and aberrant thyrocyte HLA class II expression, calling the initiating event the single largest gap in the framework. Without it, primary prevention and pre-seroconversion intervention have no target. Resolution needs a longitudinal pre-disease cohort, for example first-degree relatives followed from euthyroid antibody-negative baseline, with serial immune phenotyping, autoantibody titres, microbiome and epigenetic sampling, so that the ordering of events can be observed rather than inferred from cross-sectional patient data.
By what effector mechanism is the thyroid destroyed in patients who have the ultrasound and functional picture of Hashimoto's thyroiditis but no detectable anti-TPO or anti-thyroglobulin antibodies?
Seronegative disease is a real and reproducible phenotype in both children and adults, and it is consistently milder. It qualifies the entry's autoantibody-centred serology without refuting it, because the antibodies plausibly amplify severity rather than being required for destruction. What is missing is any positive account of the effector mechanism in these patients: whether they carry sub-threshold or intrathyroidal-only antibody, whether the infiltrate is T-cell dominant without germinal-centre B-cell help, or whether some of them are not autoimmune at all. The paediatric series raises the last possibility directly, noting its seronegative group is clinically superimposable on overweight children with the same ultrasound changes and no antibodies, a reversible condition. Deep immune profiling of seronegative thyroid tissue against seropositive and healthy controls, with B-cell and T-cell receptor repertoire sequencing, would separate these.
Show evidence (2 references)
"Prevalence of seronegative Hashimoto's thyroiditis in this cohort was 12.3% (19/154)."
Establishes that a seronegative group exists and quantifies it in one paediatric cohort of 154. The figure is cohort-specific and should not be read as a general case fraction.
"These results suggest an autoimmune etiology of SN-CAT, which, however, seems to have a milder clinical course when compared with CAT."
Independent adult case-control series reaching the same conclusion, with lower TSH, higher free T4, smaller thyroid volume and a lower prevalence of overt hypothyroidism than seropositive disease.
Is IgG4 thyroiditis a histopathological variant of Hashimoto's thyroiditis or a thyroid manifestation of systemic IgG4-related disease that should be modelled separately?
Attached to
A surgical series separating 105 Hashimoto cases by IgG4 immunostaining found the IgG4 group differs on age, sex ratio, rate of progression, autoantibody level, and histology, with a fibrosis-dominant picture that the T-cell and autoantibody destruction model curated in this entry does not explain well. The same study rules out the simplest reconciliation, that IgG4 thyroiditis is just the fibrous variant, since the two groups only partially overlap. This entry currently has no has_subtypes block and treats Hashimoto's thyroiditis as a single phenotype, so the question is recorded here rather than resolved by inventing a subtype. Deciding it needs comparative multi-omics of IgG4 thyroiditis against classical Hashimoto and against systemic IgG4-related disease. Note the reported proportion is a fraction of a thyroidectomy series, so it cannot be carried over as a prevalence in the general Hashimoto population.
Show evidence (1 reference)
"IgG4 thyroiditis was associated with a patient population of a younger age, a lower female-to-male ratio, rapid progression, higher levels of thyroid autoantibodies, subclinical hypothyroidism, and diffuse sonographic echogenicity."
Documents the clinical and serological separation between the IgG4 and non-IgG4 groups within a single Hashimoto surgical cohort, which is what makes the entity question worth posing.
Does constitutive CXCL13-CXCR5-driven plasma B cell homing to the female thyroid explain the marked female predominance of Hashimoto's thyroiditis?
Attached to
The entry records a female-predominant autoimmune disease without offering any mechanism for the sex bias. A 2024 study of thyroids deliberately screened to exclude clinical autoimmune disease found sex differences in plasma-B-cell gene programmes and localised the recruitment to the CXCL13-CXCR5 axis by single-cell and spatial transcriptomics. If a B-cell-permissive niche is already present in the healthy female thyroid, then the sex bias would sit upstream of everything curated here, in the baseline tissue state rather than in the disease process. Recorded as an emerging hypothesis rather than wired as a causal edge, because the study is in non-diseased tissue and the link to disease incidence is the authors' own inference, framed as a possible contribution.
Show evidence (1 reference)
"Single-cell RNA-seq and spatial transcriptomic analyses further revealed that the CXCL13-CXCR5 signaling axis plays a pivotal role in recruiting and organizing plasma B cells within the thyroid tissue."
Identifies the chemokine axis organising plasma B cells in thyroid tissue, the proposed substrate for a sex-biased predisposition.
Can any intervention halt or reverse the autoimmune process in Hashimoto's thyroiditis, as opposed to replacing the hormone the destroyed gland no longer makes or lowering an antibody titre?
Attached to
Every treatment curated in this entry is either replacement, which bypasses the lesion, or a biomarker-level modulator. Selenium lowers thyroid peroxidase antibody but a 412-patient double-blind trial already recorded here found no quality-of-life benefit over placebo, and a GRADE overview rates the antibody effect itself as low certainty, so the biomarker-outcome dissociation is documented rather than hypothetical. The one report of genuine disease modification is a single patient whose antibodies normalised and who came off levothyroxine while taking a JAK inhibitor for an unrelated indication. That is a lead, not a therapy. Resolution needs a randomised trial in early seropositive disease with preservation of thyroid function as the primary endpoint, not antibody titre.
Show evidence (2 references)
"We report a case of a 44-year-old woman with both alopecia universalis and HT who experienced normalization of TPO antibody levels, no longer requiring thyroid hormone treatment following JAK inhibitor therapy for alopecia universalis-suggesting possible reversal of HT."
The strongest available signal that the destructive process is pharmacologically reversible, and simultaneously the measure of how thin that evidence is. The source claims only possible reversal in one patient.
"Although selenium supplementation might reduce TPO-Ab levels at 3 and 6 months and Tg-Ab levels at 3 and 6 months in the non-LT4-treated population, this was based on a low certainty of evidence."
An overview of six systematic reviews covering 75 randomised trials rates the certainty of even the antibody-lowering effect as low, which is why selenium cannot be counted as disease-modifying therapy.
Does blocking exosome release, or supplying engineered mesenchymal stem cell-derived exosomes, restore immune homeostasis in human Hashimoto's thyroiditis, or is the effect confined to the cell and animal systems it has been shown in?
Attached to
The entry now curates three exosome-dependent mechanisms upstream of thyrocyte destruction, and none of the four treatments it lists acts on any of them: levothyroxine replaces the missing hormone, and selenium and vitamin D are supplements with weak or absent disease-modifying effect. That makes exosome release a stated therapeutic direction for a disease whose curated therapy is entirely downstream of the lesion, which is why the gap is worth recording rather than leaving implicit. What is missing is any human evidence. GW4869 is a neutral sphingomyelinase inhibitor used as a laboratory tool for blocking exosome secretion; it has no approved clinical indication, no trial in thyroid autoimmunity, and no NCIT clinical-intervention identity in this disease, so it is deliberately not curated as a treatment here. Engineered MSC-derived exosomes are at the same stage. Resolving this needs, at minimum, a demonstration that exosome blockade changes thyroid autoimmunity in an immunocompetent in vivo model of HT rather than in cell co-culture, followed by a safety-and-target-engagement study in humans — exosome secretion is constitutive and not thyroid-specific, so the plausible off-target cost of inhibiting it systemically is itself unquantified.
Also the home of a deferred design question raised in review of PR #12110: whether exosome-mediated intercellular signalling should become a pathophysiology node in its own right, with downstream edges into the three nodes listed in attaches_to. It would make the mechanism queryable and would give this therapeutic direction a target_mechanisms anchor, which it currently lacks. Deferred rather than done here because the cited review is a single secondary source: it establishes that exosomes carry these three cargoes, but a node asserting exosome signalling as a discrete causal step should rest on the primary studies, and building it would also mean deciding whether one node covers all three cargoes or each cargo is its own. Recorded so the option is not lost.
Show evidence (1 reference)
"Therapeutically, inhibition of exosome release (e.g., GW4869) and the use of engineered mesenchymal stem cell-derived exosomes demonstrate promising potential for restoring immune homeostasis."
The sentence that states the therapeutic direction, and the reason it is recorded as a gap rather than a treatment. It is the review's forward-looking synthesis of preclinical work, naming no study design, model, species or outcome measure, so it is graded OTHER: there is no single study type behind it to classify.
Pathophysiology
12Thyroglobulin Hyperiodination and Neoantigen Formation
Excess iodide drives heavier iodination of thyroglobulin during hormone synthesis, and the more heavily iodinated protein carries altered epitopes that are more immunogenic than lightly iodinated Tg. This iodine-dependent neoantigen state is the proximate biochemical step through which chronic iodine excess presents modified self-antigen to the immune system, and is the intermediate node inserted between the iodine-excess exposure and the loss of tolerance.
Downstream
Presentation of the more immunogenic hyperiodinated thyroglobulin promotes autoreactive recognition of thyroid self-antigen, contributing to the breakdown of tolerance.
Show evidence (1 reference)
"Chronic exposure to excess iodine intake induces autoimmune thyroiditis, partly because highly iodinated thyroglobulin (Tg) is more immunogenic."
Names highly iodinated thyroglobulin as the more immunogenic species, identifying the intermediate biochemical state linking iodine excess to the autoimmune response.
Thyroidal Oxidative Stress from Selenoprotein Insufficiency
Thyroid hormone synthesis generates hydrogen peroxide at the apical thyrocyte surface, which selenoprotein glutathione peroxidases normally detoxify. When selenium supply is low these selenoenzymes are limiting, so peroxide accumulates and oxidatively injures thyroid follicular cells. This oxidative thyrocyte injury and antigen release is the mechanism node downstream of the "Selenium Deficiency" state and upstream of the loss of tolerance.
Downstream
Oxidative thyrocyte injury releases and modifies sequestered thyroid antigens, promoting autoreactive priming and loss of tolerance.
Show evidence (2 references)
"the glutathione peroxidases protect the thyroid by removing excessive hydrogen peroxide produced for Tg iodination"
Identifies selenoprotein glutathione peroxidases as the thyroid's defense against the hydrogen peroxide of hormone synthesis, so their insufficiency in selenium deficiency leaves the gland exposed to oxidative injury.
"The data indicate an increased incidence of TPO-Ab seroconversion with low Se supply and support the hypothesis that Se deficiency contributes to HT as a modifiable risk factor."
Prospective cohort evidence that low selenium status raises the incidence of thyroid autoantibody seroconversion, linking this oxidative-stress state to onset of autoimmunity.
Impaired Vitamin D-Dependent Immune Tolerance
Vitamin D signaling supports tolerogenic dendritic cells and regulatory T-cell function, an immunomodulatory brake that favors self-tolerance. Low vitamin D status weakens this brake and is proposed to permit escape from immune regulation. The direction of this association is unsettled: the cited cross-sectional finding is that levels are lower in people who already have the disease, and part of the same nutritional-risk literature attributes the low levels to the autoimmune process itself (including vitamin D receptor dysfunction) rather than the reverse.
Downstream
Weakened vitamin D-dependent immunoregulation is proposed to lower the threshold for loss of tolerance to thyroid antigens, though the causal direction is not established.
Show evidence (2 references)
"Vitamin D carries out an immunomodulatory role that appears to promote immune tolerance."
States vitamin D's immunomodulatory, tolerance-promoting role, the basis for treating its deficiency as a state of weakened immune regulation.
"Hashimoto's thyroiditis (HT) is marked by self-tissue destruction as a consequence of an alteration in the adaptive immune response that entails the evasion of immune regulation."
Frames HT as evasion of immune regulation, the tolerance failure that impaired vitamin D-dependent immunomodulation is proposed to promote.
Hepatitis C Virus-Associated Thyroid Immune Activation
The specific virus with human evidence here is hepatitis C virus (HCV; chronic HCV infection, MONDO:0005354), which is associated with thyroid autoimmunity and hypothyroidism. Molecular mimicry between viral and thyroid antigens and bystander activation of autoreactive lymphocytes are the usual mechanistic proposals, but the cited evidence is an epidemiological association, and interferon-based antiviral therapy for HCV is itself thyrotoxic, which confounds it. This HCV-associated immune-activation state is the intermediate node between the HCV-infection exposure and the loss of tolerance.
Downstream
Antiviral immune activation is proposed to break tolerance to thyroid antigens via molecular mimicry or bystander activation, a mechanism not established by the cited association.
Show evidence (1 reference)
"Many studies showed that HCV is associated with thyroid autoimmunity and hypothyroidism, in patients with chronic HCV hepatitis (CHC); a significant link has been shown also between HCV-related mixed cryoglobulinemia and risk for GD."
Reports the epidemiological association of chronic HCV infection with thyroid autoimmunity and hypothyroidism, the observation behind this HCV-associated immune-activation state.
Loss of Immune Tolerance to Thyroid Antigens
Susceptibility variants in T-cell regulatory and immune-checkpoint genes (HLA class II, CTLA4, PTPN22, LAG3) act together with environmental triggers (iodine excess, selenium/vitamin D status, viral infection) to break self-tolerance to thyroid peroxidase and thyroglobulin, the initiating lesion that licenses autoreactive T- and B-cell responses against the thyroid. A rare LAG3 start-codon variant that lowers the inhibitory checkpoint LAG-3 exemplifies how impaired T-cell down-regulation predisposes to autoimmune thyroid disease.
Downstream
Breakdown of tolerance permits autoreactive T cells and an interferon-rich milieu that drives thyroid follicular cells to present antigen.
Loss of tolerance licenses autoreactive T and B lymphocytes that traffic into and accumulate within the thyroid gland.
Escape from regulatory control shifts the CD4 compartment toward the IL-17-producing effector program, so the Th17/Treg set point moves with the loss of tolerance rather than independently of it.
Show evidence (2 references)
"Multiomics analysis yields 235 candidate genes outside the MHC-region and the findings highlight the importance of genes involved in T-cell regulation."
A large AITD GWAS meta-analysis localizes susceptibility to T-cell regulatory genes, supporting loss of T-cell tolerance as the initiating mechanism.
"exosomal HSP60 released from IFN‑γ-stimulated thyroid follicular cells acts as an autoantigen cross‑reacting with TPO and TG, promoting thyrocyte injury through antigen-antibody interactions"
Identifies exosomal HSP60 from inflamed thyroid follicular cells as a cross-reactive autoantigen that mimics TPO and thyroglobulin epitopes, directly driving the loss of tolerance to thyroid self-antigens.
Th17/Treg Imbalance
The CD4 T helper compartment in Hashimoto's thyroiditis is shifted away from Foxp3 regulatory commitment and toward the RORgt-driven, IL-17-producing Th17 program. Regulatory T cell frequency, Foxp3 transcript, and the Treg/Th17 ratio are all lower in patients, IL-17A is higher, and the ratio tracks inversely with thyroid autoantibody titres and TSH. IL-17 signalling in turn raises IL-6, CXCL10 and ICAM-1, feeding the intrathyroidal infiltrate. Whether this imbalance is an upstream initiator or a parallel feature of established disease is not settled: the human data are cross-sectional, and the claim that Th17 predominance precedes Th1-mediated destruction is a review-level synthesis with no longitudinal human series behind it (see notes).
Downstream
IL-17 signalling through IL-17RA raises chemokine and adhesion-molecule expression in the gland, amplifying recruitment and retention of the intrathyroidal lymphocytic infiltrate.
Show evidence (5 references)
"We found that the percentage of Treg cells, Foxp3 mRNA levels, and the ratio of Treg/Th17 cells were all significantly lower in HT patients, while Th17 cell percentages and RORgammat mRNA levels were significantly higher."
Direct human measurement of the two arms of this node in patient peripheral blood: regulatory frequency and Foxp3 down, Th17 frequency and RORgt up.
"The ratio of Treg/Th17 cells was negatively correlated with the levels of serum thyroperoxidase antibody, thyroglobulin antibody, and thyrotropin (TSH) in HT patients."
Ties the magnitude of the imbalance to the serologic and hormonal severity markers of the disease, which is what makes it a mechanism node rather than an incidental immunophenotype. The design is cross-sectional, so it establishes covariation, not direction.
"Serum and tissue IL-17 concentrations correlate positively with TPOAb or TgAb titres and early fibrosis"
Extends the correlation from circulating cell frequencies to IL-17 protein in serum and in thyroid tissue, and links it to early fibrosis.
+ 2 more references
Thyrocyte Antigen Presentation
Under interferon-gamma and TNF-alpha exposure, thyroid follicular cells aberrantly upregulate MHC class II together with the invariant chain CD74 and its ligand MIF, becoming non-professional antigen-presenting cells. This amplifies local antigen presentation and ligand-receptor cross-talk with infiltrating immune cells, sustaining and propagating the intrathyroidal autoimmune response.
Downstream
Thyrocyte antigen presentation and chemokine expression recruit and activate infiltrating lymphocytes within the gland.
Show evidence (1 reference)
"We identify damaged antigen-presenting TFCs with upregulated CD74 and MIF expression in thyroid samples from AITD patients."
Spatial transcriptomics shows thyroid follicular cells act as antigen-presenting cells via CD74/MIF upregulation, driving local autoimmunity.
Autoimmune Thyroid Destruction
T cell-mediated and antibody-mediated destruction of thyroid follicular cells leads to progressive loss of thyroid function. Anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin antibodies are characteristic.
Downstream
Progressive cytotoxic and antibody-mediated loss of hormone-producing follicular cells depletes the gland's capacity to synthesize T3 and T4, producing thyroid hormone deficiency.
Early inflammatory destruction of follicles can release preformed stored hormone, producing a transient thyrotoxic (hashitoxicosis) phase before glandular reserve is exhausted and hypothyroidism supervenes.
Show evidence (4 references)
"We identify damaged antigen-presenting TFCs with upregulated CD74 and MIF expression in thyroid samples from AITD patients."
Spatial transcriptomics demonstrates that thyroid follicular cells actively participate in autoimmune destruction by presenting antigens via CD74/MIF upregulation.
"Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
Confirms the characteristic antibody profile and lymphocytic infiltration pattern in Hashimoto's thyroiditis.
"Through this review, we aim to establish mechanistic connections between ICI pharmacodynamics and thyroid tissue immunopathology."
ICI-induced thyroiditis provides a mechanistic model that mirrors the autoimmune destruction seen in spontaneous Hashimoto's thyroiditis.
+ 1 more reference
Lymphocytic Infiltration
Dense lymphocytic infiltration of the thyroid gland with germinal center formation. CD4+ T cells, CD8+ T cells, and B cells accumulate in the thyroid parenchyma.
Downstream
Infiltrating cytotoxic T cells, autoantibody-producing B/plasma cells, and inflammatory macrophages execute follicular-cell killing.
Dense inflammatory infiltration and lymphoid-follicle formation enlarge the gland, producing the characteristic diffuse goiter.
The infiltrating lymphocytes are the effector killers of the follicular cells, and the cytokines they release are what render otherwise resistant thyrocytes killable through Fas.
Show evidence (4 references)
"Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
Lymphocytic infiltration is a defining histological feature of Hashimoto's thyroiditis.
"Here, we use spatial transcriptomics to explore the molecular architecture, heterogeneity and location of different cells present in the thyroid tissue, including thyroid follicular cells (TFCs), stromal cells such as fibroblasts, endothelial cells, and thyroid infiltrating lymphocytes."
Spatial analysis confirms the presence and organization of infiltrating lymphocytes in the thyroid microenvironment.
"Intrathyroidal LFs were microanatomically very similar to canonical LFs, ie, they had well-developed germinal centers with mantle, light, and dark zones and each of these zones contained B and T lymphocytes, follicular dendritic and interdigitating dendritic cells with typical phenotypes."
Grounds the germinal-centre component of this node. Direct comparison against tonsil and lymph node follicles shows the intrathyroidal lymphoid follicles are structurally complete germinal centres, not merely dense aggregates, and the same study found most of them bind thyroglobulin and thyroperoxidase, so they are committed to thyroid self-antigen.
+ 1 more reference
Cytokine-Sensitized Fas-Mediated Thyrocyte Apoptosis
Normal thyroid follicular cells express Fas but resist Fas-mediated apoptosis: signalling is blocked downstream of the proximal caspases. Interferon gamma together with interleukin 1 beta lifts that block by raising surface Fas, procaspases 7, 8 and 10, and the proapoptotic BH3 protein Bid, so that Fas ligation then cleaves caspases 7 and 3, engages mitochondria, and kills the cell. This cytokine gate is the reason destruction is confined to the inflamed gland. The killing is executed by the intrathyroidal lymphocytes rather than by the thyrocytes themselves, and it proceeds without perforin. It is not exclusively a Fas/FasL process: ex vivo killing is only partially blocked by disrupting Fas/FasL and a caspase-independent route appears to coexist.
Downstream
Cytokine-sensitized Fas ligation kills follicular cells, which is the cellular execution step of the destructive process.
Show evidence (3 references)
"Normal thyroid cells are resistant to Fas-mediated apoptosis in vitro but can be sensitized by the unique combination of interferon-gamma and IL-1beta cytokines."
Establishes the cytokine gate that defines this node in primary human thyroid cells: resistance at baseline, sensitivity only after interferon gamma plus interleukin 1 beta.
"In Hashimoto's thyroiditis, thyrocytes were poorly functional while lymphocytes were able to operate as effectors."
Identifies which cell does the killing. In Hashimoto glands only the lymphocytes killed Fas-expressing targets, which argues against the thyrocyte fratricide reading of Fas/FasL and places the effector role on the infiltrate, consistent with the upstream edge from Lymphocytic Infiltration.
"Cell death was only partially dependent on Fas/Fas ligand but it was trypsin-sensitive. Blocking perforin did not affect Fas-expressing target killing while caspase inhibitors had a consistent although limited effect."
Bounds the claim in both directions. Perforin blockade does nothing, so the pathway is perforin-independent as curated; but Fas/FasL disruption only partially blocks killing and caspase inhibition has limited effect, so a coexisting caspase-independent route is implied and Fas/FasL cannot be called the sole or fully dominant mechanism.
NF-κB-IL-6 Signaling Pathway Activation
Genetic regulation of NF-κB and IL-6 signaling modulates the autoimmune response in Hashimoto's thyroiditis. CCDC77 and SLC45A3 are novel genetic modifiers that regulate NF-κB pathway activation and IL-6 production. CCDC77 acts as a protective regulator (knockdown exacerbates thyroid damage), while SLC45A3 acts as a disease-promoting factor (knockdown alleviates thyroiditis). The NF-κB-IL-6 axis modulates immune cell activation and thyroid-targeted autoimmunity.
Downstream
Genetic modulation of the NF-κB-IL-6 axis tunes immune-cell activation and recruitment, amplifying the intrathyroidal lymphocytic infiltrate.
Show evidence (3 references)
"MR analysis identified CCDC77 and SLC45A3 as key genes associated with both IL-6 and HT."
Two-sample Mendelian randomization using human eQTL/GWAS data identified CCDC77 and SLC45A3 as IL-6-linked genes associated with Hashimoto's thyroiditis.
"In vivo experiments showed that knockdown of CCDC77 exacerbated thyroid damage, increased serum anti-thyroperoxidase antibody (TPOAb), anti-thyroglobulin antibody (TGAb), and IL-6 levels, while reduced free triiodothyronine (FT3) and free thyroxine (FT4). Conversely, SLC45A3 knockdown alleviated..."
In vivo validation in NOD mice demonstrates that CCDC77 and SLC45A3 regulate HT progression through the NF-κB-IL-6 signaling axis; CCDC77 is a protective modulator while SLC45A3 is disease-promoting.
"Patient‑derived exosomes containing elevated TPO and MHC‑II activate dendritic cells via TLR2/3 and NF‑κB pathways, driving Th1/Th17 polarization while suppressing Treg differentiation"
Identifies patient-derived exosomes as an upstream activator of the NF-κB signaling this node describes, acting on dendritic cells through TLR2/3. It adds a route to NF-κB pathway activation that is independent of the CCDC77/SLC45A3 genetic modifiers curated on the same node, and places dendritic cells alongside macrophages as a cell type in which the axis operates.
Thyroid Hormone Deficiency
Progressive destruction of thyroid tissue leads to decreased production of T3 and T4, resulting in hypothyroidism with elevated TSH through negative feedback.
Downstream
Insufficient T3/T4 output with compensatory TSH elevation manifests clinically as primary hypothyroidism.
Show evidence (1 reference)
"Due to the progressive destruction of cells, AITD can lead to subclinical or overt hypothyroidism."
Progressive thyroid destruction in Hashimoto's thyroiditis results in hypothyroidism through loss of hormone-producing cells.
Pathograph
Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Phenotypes
11Digestive 1
Constipation
FREQUENT
HP:0002019
Human Phenotype Ontology (HP)
Relation: this clinical feature is this phenotype
This clinical feature is Constipation (HP:0002019). HP:0002019 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
"Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
Constipation is a recognized symptom in hypothyroid states.
Endocrine 3
Goiter
FREQUENT
HP:0000853
Human Phenotype Ontology (HP)
Relation: this clinical feature is this phenotype
This clinical feature is Goiter (HP:0000853). HP:0000853 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
"Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
Goiter develops due to lymphocytic infiltration and inflammatory enlargement of the thyroid gland.
Hypothyroidism
HP:0000821
Human Phenotype Ontology (HP)
Relation: this clinical feature is this phenotype
This clinical feature is Hypothyroidism (HP:0000821). HP:0000821 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
"developing a primary hypothyroidism"
This review states Hashimoto thyroiditis develops a primary hypothyroidism.
Hashitoxicosis
Hyperthyroidism
HP:0000836
Human Phenotype Ontology (HP)
Relation: this clinical feature is this phenotype
This clinical feature is Hashitoxicosis (transient hyperthyroidism), annotated with Hyperthyroidism (HP:0000836). HP:0000836 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
"at presentation patients can be euthyroid or even hyperthyroid"
This clinical-criteria review notes patients may be hyperthyroid at presentation of Hashimoto thyroiditis.
Integument 1
Dry Skin
FREQUENT
HP:0000958
Human Phenotype Ontology (HP)
Relation: this clinical feature is this phenotype
This clinical feature is Dry Skin (HP:0000958). HP:0000958 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
"Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
Dry skin is a common dermatologic manifestation of hypothyroidism.
Metabolism 3
Vitamin D Deficiency
Decreased circulating vitamin D concentration
HP:0100512
Human Phenotype Ontology (HP)
Relation: this clinical feature is this phenotype
This clinical feature is Vitamin D deficiency, annotated with Decreased circulating vitamin D concentration (HP:0100512). HP:0100512 is a phenotype from the Human Phenotype Ontology.
HP:0100512 is bound here as an upstream risk state, not a manifestation: because this phenotype has a sequelae edge into a pathophysiology node, the KGX/HPOA exporters export it as a direction-neutral `MONDO:0007699 biolink:associated_with HP:0100512` rather than `has_phenotype`. (This supersedes the earlier workaround of binding MONDO:0100471 to dodge the has_phenotype inversion; the direction-aware exporter makes the HP binding correct.) The association is cross-sectional and may be bidirectional; part of the nutritional-risk literature (PMID:28290237) attributes low vitamin D to the autoimmune process itself, including vitamin D receptor dysfunction.
Show evidence (1 reference)
"There is extensive literature confirming that vitamin D levels are significantly lower in HT patients compared to healthy people."
Grounds the vitamin D-deficiency state as a finding associated with HT.
Selenium Deficiency
Decreased circulating selenium concentration
HP:0033192
Human Phenotype Ontology (HP)
Relation: this clinical feature is this phenotype
This clinical feature is Selenium deficiency, annotated with Decreased circulating selenium concentration (HP:0033192). HP:0033192 is a phenotype from the Human Phenotype Ontology.
HP:0033192 is bound here as an upstream risk state, not a manifestation. The KGX/HPOA exporters detect that (this phenotype has a sequelae edge into a pathophysiology node) and export it as a direction-neutral `MONDO:0007699 biolink:associated_with HP:0033192` rather than `has_phenotype`, so the export does not invert the cited prospective cohort in which low selenium supply *precedes* TPO-Ab seroconversion. MONDO has no human selenium-deficiency class (MONDO:1017720 is explicitly non-human-animal, MONDO:0000241 Keshan disease is a distinct cardiomyopathy), so HP is the only grounding available - and, with the direction-aware exporter, the correct one.
Show evidence (1 reference)
"The data indicate an increased incidence of TPO-Ab seroconversion with low Se supply and support the hypothesis that Se deficiency contributes to HT as a modifiable risk factor."
Prospective cohort evidence grounding selenium deficiency as a modifiable risk state associated with onset of thyroid autoimmunity.
Cold Intolerance
FREQUENT
HP:6000855
Human Phenotype Ontology (HP)
Relation: this clinical feature is this phenotype
This clinical feature is Cold Intolerance (HP:6000855). HP:6000855 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
"Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
Cold intolerance is a common symptom of hypothyroidism in Hashimoto's thyroiditis.
Nervous System 1
Depression
HP:0000716
Human Phenotype Ontology (HP)
Relation: this clinical feature is this phenotype
This clinical feature is Depression (HP:0000716). HP:0000716 is a phenotype from the Human Phenotype Ontology.
Frequency band deliberately omitted: the only cited source lists depression among the "most common presenting symptoms", which conflicts with the previously curated OCCASIONAL (5-29%) band and provides no quantitative estimate. Per the frequency-evidence guidelines, no band is asserted.
Show evidence (1 reference)
"The most common presenting symptoms may include anxiety, negative mood, depression, dry skin, cold intolerance, puffy eyes, muscle cramps and fatigue, deep voice, constipation, slow thinking and poor memory."
Depression is reported among common presenting symptoms in Hashimoto's thyroiditis.
Constitutional 1
Fatigue
VERY_FREQUENT
HP:0012378
Human Phenotype Ontology (HP)
Relation: this clinical feature is this phenotype
This clinical feature is Fatigue (HP:0012378). HP:0012378 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
"Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
Hashimoto-associated hypothyroidism commonly presents with fatigue.
Growth 1
Weight Gain
FREQUENT
Increased body weight
HP:0004324
Human Phenotype Ontology (HP)
Relation: this clinical feature is this phenotype
This clinical feature is Weight Gain, annotated with Increased body weight (HP:0004324). HP:0004324 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
"Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
Weight gain is a common hypothyroid symptom in Hashimoto's thyroiditis.
Genetic Associations
7
HLA-DR3
(Risk Factor)
Show evidence (1 reference)
"AITD susceptibility genes can be categorized as either thyroid specific (Tg, TSHR) or immune-modulating (FOXP3, CD25, CD40, CTLA-4, HLA), with HLA-DR3 carrying the highest risk."
HLA-DR3 is identified as a major immune-genetic risk factor in autoimmune thyroid disease, including HT.
HLA-DR4
(Risk Factor)
Show evidence (1 reference)
"'DRB1*04+GG' (PL: p=0.003; HT: p=0.008)"
HLA-DRB1*04 contributes to susceptibility in combination with CTLA4 risk genotype in HT cohorts.
CTLA4
(Risk Factor)
Show evidence (1 reference)
"CTLA4 polymorphisms were associated with an elevated risk of a thyroid disease and poorer glycemic control;"
CTLA4 polymorphisms are associated with increased autoimmune thyroid disease risk.
PTPN22
(Risk Factor)
Show evidence (1 reference)
"This meta-analysis showed that the PTPN22 R620W polymorphism is associated with the risk of GD and HT in the overall study population."
Meta-analysis supports PTPN22 as a susceptibility locus for Hashimoto's thyroiditis.
LAG3
(Risk Factor)
Show evidence (1 reference)
"rs781745126-T reduces mRNA and surface expression of the inhibitory immune checkpoint LAG-3 co-receptor on activated lymphocyte subsets and halves LAG-3 levels in plasma among heterozygotes."
A rare LAG3 5'-UTR start-codon variant lowers the inhibitory checkpoint LAG-3, unleashing autoreactive lymphocytes and conferring the largest single-variant AITD risk (OR 3.42).
CCDC77
(Protective)
Show evidence (2 references)
"MR analysis identified CCDC77 and SLC45A3 as key genes associated with both IL-6 and HT."
Mendelian randomization using eQTL/GWAS data identifies CCDC77 as genetically associated with HT through IL-6.
"knockdown of CCDC77 exacerbated thyroid damage, increased serum anti-thyroperoxidase antibody (TPOAb), anti-thyroglobulin antibody (TGAb), and IL-6 levels, while reduced free triiodothyronine (FT3) and free thyroxine (FT4)."
NOD mouse knockdown demonstrates that CCDC77 loss exacerbates thyroid autoimmunity, confirming CCDC77 as protective through NF-κB-IL-6 signaling.
SLC45A3
(Risk Factor)
Show evidence (2 references)
"MR analysis identified CCDC77 and SLC45A3 as key genes associated with both IL-6 and HT."
Mendelian randomization using eQTL/GWAS data identifies SLC45A3 as genetically associated with HT through IL-6.
"SLC45A3 knockdown alleviated thyroiditis, reduced antibody levels, and improved thyroid function."
NOD mouse knockdown shows that SLC45A3 reduction ameliorates thyroid autoimmunity, confirming SLC45A3 as a risk factor via NF-κB-IL-6 axis.
Medical Actions
4
Levothyroxine
Thyroid hormone replacement therapy, the mainstay of treatment. It corrects the hormone deficiency by bypassing the destroyed gland but does not address the upstream autoimmunity or inflammation.
Show evidence (1 reference)
"Management includes thyroid hormone replacement, ideally levothyroxine."
Levothyroxine is standard hormone replacement therapy in hypothyroidism due to HT.
Selenium Supplementation
Adjunctive selenium can lower thyroid autoantibody titers, but a 2024 multicenter double-blind RCT found no quality-of-life benefit over placebo in LT4-treated autoimmune thyroiditis, illustrating a biomarker-outcome dissociation.
Show evidence (2 references)
"In people with HT without THRT, selenium was effective and safe in lowering TSH, TPOAb, and MDA levels."
Meta-analysis supports selenium as a potential adjunct in selected HT patients.
"no difference in any of the ThyPRO-39 scales was found between the selenium group and the placebo group after 12 months of intervention"
A 412-patient double-blind RCT found selenium gave no quality-of-life benefit over placebo despite biochemical antibody effects, tempering enthusiasm for routine use.
Vitamin D Supplementation
Cholecalciferol supplementation in vitamin D-deficient HT patients can lower thyroid autoantibody titers; evidence is preliminary and further randomized trials are needed.
Show evidence (1 reference)
"after the supplementation with cholecalciferol in patients with HT and vitamin D deficiency, thyroid autoantibody titers decreased significantly."
Supports vitamin D repletion as an adjunct that lowers autoantibody titers in deficient HT patients.
Monitoring
Regular TSH monitoring to adjust replacement dose.
Show evidence (1 reference)
"Thyroid hormone should be titrated based on goal TSH values, symptoms, and potential treatment adverse effects."
Ongoing TSH-based monitoring is required to titrate thyroid hormone replacement.
Environmental Factors
4Iodine Excess
Can trigger or worsen disease
Show evidence (1 reference)
"Chronic exposure to excess iodine intake induces autoimmune thyroiditis, partly because highly iodinated thyroglobulin (Tg) is more immunogenic."
Excess iodine exposure is associated with autoimmune thyroiditis in HT-focused nutritional risk literature.
Low Dietary Selenium Intake
May increase risk
Show evidence (1 reference)
"The data indicate an increased incidence of TPO-Ab seroconversion with low Se supply and support the hypothesis that Se deficiency contributes to HT as a modifiable risk factor."
Prospective cohort data support selenium deficiency as a modifiable risk factor for Hashimoto's thyroiditis.
Hepatitis C Virus Infection
HCV is the specific virus with human evidence; other candidate viruses are unverified here (see the pathophysiology node notes).
Show evidence (1 reference)
"Many studies showed that HCV is associated with thyroid autoimmunity and hypothyroidism, in patients with chronic HCV hepatitis (CHC); a significant link has been shown also between HCV-related mixed cryoglobulinemia and risk for GD."
Chronic hepatitis C virus infection is associated with thyroid autoimmunity and hypothyroidism.
Low Vitamin D Intake and Cutaneous Synthesis
Low vitamin D status is consistently associated with HT; vitamin D has an immunomodulatory role promoting immune tolerance, and its deficiency is a candidate modifiable risk factor.
Show evidence (1 reference)
"There is extensive literature confirming that vitamin D levels are significantly lower in HT patients compared to healthy people."
A 2024 review confirms vitamin D levels are significantly lower in HT patients, supporting deficiency as an associated environmental risk factor.
Biochemical Markers
5
TSH
(Elevated)
Context: Primary hypothyroidism
Pathograph Readouts
Readout Of
Thyroid Hormone Deficiency
Positive
Diagnostic
Compensatory TSH elevation is the biochemical hallmark that reports the thyroid hormone synthesis deficit in primary hypothyroidism.
Show evidence (1 reference)
"Overt hypothyroidism occurs when a patient has an elevated TSH level and a low free T4 level with symptoms of hypothyroidism."
Elevated TSH is a core biochemical feature of overt hypothyroidism in Hashimoto's disease.
Free T4
(Decreased)
Context: Overt hypothyroidism
Pathograph Readouts
Readout Of
Thyroid Hormone Deficiency
Negative
Diagnostic
Low free T4 directly measures the reduced thyroid hormone output; lower values track with more severe hormone deficiency.
Show evidence (1 reference)
"Overt hypothyroidism occurs when a patient has an elevated TSH level and a low free T4 level with symptoms of hypothyroidism."
Low free T4 defines overt hypothyroidism and supports this biochemical pattern.
Anti-TPO Antibodies
(Elevated)
Context: Diagnostic marker
Pathograph Readouts
Readout Of
Autoimmune Thyroid Destruction
Present Absent
Diagnostic
Anti-TPO positivity reports the ongoing autoimmune attack on thyroid peroxidase and is the principal serologic marker of the destructive process.
Show evidence (1 reference)
"Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
Supports anti-TPO positivity as a characteristic diagnostic marker in HT.
Anti-Thyroglobulin Antibodies
(Elevated)
Context: Present in majority of patients
Pathograph Readouts
Readout Of
Autoimmune Thyroid Destruction
Present Absent
Diagnostic
Anti-thyroglobulin positivity reflects humoral autoimmunity against thyroglobulin accompanying follicular destruction.
Show evidence (1 reference)
"Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
Supports elevated anti-thyroglobulin antibodies in HT.
Circulating Exosomal Proteomic Signature
(Elevated)
Context: Emerging, not clinically validated. Reported as a distinct exosomal protein profile in HT, with HGFL, FAK1 and PTN12 among the immunomodulatory proteins increased relative to controls.
Show evidence (1 reference)
"Proteomic studies further reveal distinct exosomal signatures in HT, including increased immunomodulatory proteins such as HGFL, FAK1, and PTN12."
Records the proteomic half of the cited review: circulating exosomes in HT carry a protein profile distinguishable from controls. The quoted sentence is the review's synthesis of patient-sample proteomics it did not itself perform, so it is graded HUMAN_CLINICAL for the studies described and marked REVIEW_SYNTHESIS for where the sentence sits.
Related Datasets
1
GTEx v8 Thyroid tissue RNA-seq in Hashimoto case-control analysis
gtex:GTEx_v8_Thyroid
Bulk RNA-seq analysis of thyroid tissue from GTEx v8 used in a case-control comparison of histopathologically confirmed Hashimoto's thyroiditis and matched controls.
Show evidence (1 reference)
"As part of a case–control design, we analyzed thyroid tissue RNA sequencing libraries from the Genotype-Tissue Expression Project (v8 release)."
The dataset entry captures the GTEx v8 thyroid RNA-seq source used to compare Hashimoto and control thyroid tissue transcriptomes.
Source YAML
click to showname: Hashimoto's Thyroiditis
creation_date: '2025-12-18T17:01:35Z'
description: >-
Hashimoto's thyroiditis is a chronic autoimmune disease and the leading cause
of primary hypothyroidism, in which loss of immune tolerance to thyroid
antigens (thyroid peroxidase and thyroglobulin) drives lymphocytic
infiltration and progressive destruction of thyroid follicular cells. CD4 and
CD8 T cells together with anti-TPO and anti-thyroglobulin autoantibodies
deplete the gland, producing thyroid hormone deficiency that manifests as
fatigue, weight gain, cold intolerance, and goiter. Susceptibility is
conferred by HLA and other immune-regulatory loci interacting with
environmental triggers such as iodine excess and viral infection, and
levothyroxine replacement reverses the hypothyroid syndrome.
category: Complex
parents:
- Autoimmune Disease
- Endocrine Disease
disease_term:
preferred_term: Hashimoto thyroiditis
term:
id: MONDO:0007699
label: Hashimoto thyroiditis
mechanistic_hypotheses:
- hypothesis_group_id: canonical_autoimmune_thyrocyte_destruction_model
hypothesis_label: Canonical Autoimmune Thyrocyte Destruction Model
status: CANONICAL
description: >-
Hashimoto's thyroiditis is a chronic autoimmune disease in which loss of immune tolerance to thyroid
antigens — primarily thyroid peroxidase (TPO) and thyroglobulin (Tg) — drives lymphocytic
infiltration of the thyroid gland, formation of intrathyroidal tertiary lymphoid structures, and
progressive thyrocyte destruction. CD4 Th1 and Th17 cells, CD8 cytotoxic T cells, and autoantibody-mediated
effects (anti-TPO, anti-Tg) act together to deplete follicular cells, producing primary
hypothyroidism. Susceptibility is conferred by HLA-DR3/DR5, CTLA4, PTPN22, and other immune-regulation
loci, with environmental triggers including iodine excess, viral infection, and selenium
deficiency. Levothyroxine replacement reverses the hypothyroid syndrome by bypassing the destroyed
gland, supporting glandular failure as the proximate clinical lesion in this canonical model.
notes: >-
Retained as CANONICAL. The 2026 openscientist
hypothesis-search report
(kb/hypotheses/Hashimotos_Thyroiditis/canonical_autoimmune_thyrocyte_destruction_model)
confirms 12 of 13 mechanistic claims as established. Core
effector mechanisms — Fas/FasL-mediated thyrocyte apoptosis
(sensitized by IFN-γ + IL-1β, independent of perforin/granzyme),
intrathyroidal tertiary lymphoid structures functioning as
germinal centers with RAG1/RAG2 in situ receptor revision, and
coordinated CD4 Th1/Th17 + CD8 + autoantibody (anti-TPO in
>90%) responses — are validated by histopathology, single-cell
transcriptomics, and immune-checkpoint-inhibitor-induced
thyroiditis as a natural experiment. JAK inhibition has
provided proof-of-concept reversal. Six refinements: (1) Th17/Treg
imbalance is now established as an upstream initiator
preceding Th1-mediated destruction, not captured by the seed
description; (2) IgG4-related thyroiditis (~27%) and
seronegative HT (~12%) are clinically significant subtypes the
model does not address; (3) GWAS identifies 418 independent
signals (vs ~5 canonical loci) explaining only ~5.4% of
variance, indicating extensive polygenicity; (4) the gut-thyroid
axis (molecular mimicry, SCFA depletion) provides a
mechanistic bridge from environmental triggers to immune
dysregulation; (5) thyrocyte HLA class II expression (Bottazzo
hypothesis) and NETosis are increasingly implicated;
(6) sex-specific intrathyroidal B-cell homing via CXCL13-CXCR5
helps explain the female predominance. The initial
tolerance-breaking event remains unknown and no disease-modifying
RCT has yet been completed.
evidence:
- reference: PMID:38731922
reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
explanation: >
Canonical mechanism reference used as the seed for the hypothesis-search
deep-research run. It supports the autoantibody plus lymphocytic-infiltration
core of the model, but not the full CD4 Th1/Th17, CD8,
tertiary-lymphoid-structure, or genetic-susceptibility claims in the
hypothesis description.
- reference: PMID:41748903
reference_title: "Genome-wide association analyses of autoimmune hypothyroidism reveal autoimmune and thyroid-specific contributions and an inverse relationship with cancer risk."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "we performed a genome-wide association meta-analysis of 81,718 AIHT cases in FinnGen and the UK Biobank, identifying 418 independent signals"
explanation: >-
Substantiates refinement (3) in the notes above, which until now was
asserted only in prose. The susceptibility architecture behind this
hypothesis is far more polygenic than the HLA-DR3/DR5, CTLA4 and PTPN22
loci the description names: 418 independent genome-wide significant
signals in 81,718 cases. The same study reports coding variants in LAG3,
ZAP70 and TG among the lead signals, which converges with the LAG3
variant already curated in this entry from an independent source.
- reference: PMID:29931474
reference_title: "How much of the predisposition to Hashimoto's thyroiditis can be explained based on previously reported associations?"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The variability explained by this model was assessed at only 5.4821%"
explanation: >-
Quantifies how little of the predisposition the named canonical loci
account for, supporting the same polygenicity refinement. Note the scope:
this is a seven-variable model over candidate SNPs plus HLA-DRB1
sequencing in 147 cases and 147 controls in a single Polish cohort. It is
not a variance-explained figure for the 418 GWAS signals above, and the
openscientist report's juxtaposition of the two numbers should not be read
that way.
pathophysiology:
- name: Thyroglobulin Hyperiodination and Neoantigen Formation
description: >-
Excess iodide drives heavier iodination of thyroglobulin during hormone
synthesis, and the more heavily iodinated protein carries altered epitopes
that are more immunogenic than lightly iodinated Tg. This iodine-dependent
neoantigen state is the proximate biochemical step through which chronic
iodine excess presents modified self-antigen to the immune system, and is the
intermediate node inserted between the iodine-excess exposure and the loss of
tolerance.
role: trigger
biological_scale: MOLECULAR
cell_types:
- preferred_term: Thyroid Follicular Cell
term:
id: CL:0002258
label: thyroid follicular cell
biological_processes:
- preferred_term: Thyroglobulin iodination
term:
id: GO:0006590
label: thyroid hormone generation
# The claim here is qualitative - thyroglobulin carries abnormal, more
# immunogenic iodination - not that hormone generation runs above its normal
# level. INCREASED would also contradict the DECREASED modifier this same GO
# term carries downstream on the Thyroid Hormone Deficiency node.
modifier: ABNORMAL
evidence:
- reference: PMID:28290237
reference_title: "Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Chronic exposure to excess iodine intake induces autoimmune thyroiditis, partly because highly iodinated thyroglobulin (Tg) is more immunogenic."
explanation: >-
Names highly iodinated thyroglobulin as the more immunogenic species,
identifying the intermediate biochemical state linking iodine excess to
the autoimmune response.
downstream:
- target: Loss of Immune Tolerance to Thyroid Antigens
causal_link_type: DIRECT
description: >-
Presentation of the more immunogenic hyperiodinated thyroglobulin promotes
autoreactive recognition of thyroid self-antigen, contributing to the
breakdown of tolerance.
- name: Thyroidal Oxidative Stress from Selenoprotein Insufficiency
description: >-
Thyroid hormone synthesis generates hydrogen peroxide at the apical thyrocyte
surface, which selenoprotein glutathione peroxidases normally detoxify. When
selenium supply is low these selenoenzymes are limiting, so peroxide
accumulates and oxidatively injures thyroid follicular cells. This oxidative
thyrocyte injury and antigen release is the mechanism node downstream of the
"Selenium Deficiency" state and upstream of the loss of tolerance.
role: trigger
biological_scale: CELLULAR
cell_types:
- preferred_term: Thyroid Follicular Cell
term:
id: CL:0002258
label: thyroid follicular cell
biological_processes:
- preferred_term: Peroxide detoxification by glutathione peroxidase
term:
id: GO:0042744
label: hydrogen peroxide catabolic process
modifier: DECREASED
- preferred_term: Response to oxidative stress
term:
id: GO:0006979
label: response to oxidative stress
modifier: INCREASED
chemical_entities:
- preferred_term: hydrogen peroxide
term:
id: CHEBI:16240
label: hydrogen peroxide
modifier: INCREASED
evidence:
- reference: PMID:28290237
reference_title: "Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the glutathione peroxidases protect the thyroid by removing excessive hydrogen peroxide produced for Tg iodination"
explanation: >-
Identifies selenoprotein glutathione peroxidases as the thyroid's defense
against the hydrogen peroxide of hormone synthesis, so their insufficiency
in selenium deficiency leaves the gland exposed to oxidative injury.
- reference: PMID:35789269
reference_title: "Increased Incidence of Hashimoto Thyroiditis in Selenium Deficiency: A Prospective 6-Year Cohort Study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The data indicate an increased incidence of TPO-Ab seroconversion with low Se supply and support the hypothesis that Se deficiency contributes to HT as a modifiable risk factor."
explanation: >-
Prospective cohort evidence that low selenium status raises the incidence
of thyroid autoantibody seroconversion, linking this oxidative-stress state
to onset of autoimmunity.
downstream:
- target: Loss of Immune Tolerance to Thyroid Antigens
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Peroxide-mediated thyrocyte oxidative injury and release of sequestered thyroid antigen
description: >-
Oxidative thyrocyte injury releases and modifies sequestered thyroid
antigens, promoting autoreactive priming and loss of tolerance.
- name: Impaired Vitamin D-Dependent Immune Tolerance
description: >-
Vitamin D signaling supports tolerogenic dendritic cells and regulatory
T-cell function, an immunomodulatory brake that favors self-tolerance. Low
vitamin D status weakens this brake and is proposed to permit escape from
immune regulation. The direction of this association is unsettled: the cited
cross-sectional finding is that levels are lower in people who already have
the disease, and part of the same nutritional-risk literature attributes the
low levels to the autoimmune process itself (including vitamin D receptor
dysfunction) rather than the reverse.
role: trigger
biological_scale: CELLULAR
biological_processes:
- preferred_term: Immune tolerance induction
term:
id: GO:0002507
label: tolerance induction
modifier: DECREASED
- preferred_term: Regulation of immune response
term:
id: GO:0050776
label: regulation of immune response
modifier: DECREASED
evidence:
- reference: PMID:38542128
reference_title: "Autoimmune Thyroiditis and Vitamin D."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Vitamin D carries out an immunomodulatory role that appears to promote immune tolerance."
explanation: >-
States vitamin D's immunomodulatory, tolerance-promoting role, the basis
for treating its deficiency as a state of weakened immune regulation.
- reference: PMID:38542128
reference_title: "Autoimmune Thyroiditis and Vitamin D."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Hashimoto's thyroiditis (HT) is marked by self-tissue destruction as a consequence of an alteration in the adaptive immune response that entails the evasion of immune regulation."
explanation: >-
Frames HT as evasion of immune regulation, the tolerance failure that
impaired vitamin D-dependent immunomodulation is proposed to promote.
notes: >-
Direction of effect is uncertain (reverse causation): low vitamin D in HT
patients is cross-sectional, and part of the nutritional-risk literature
(PMID:28290237) argues low vitamin D is more likely a result of the
autoimmune process, including vitamin D receptor dysfunction.
downstream:
- target: Loss of Immune Tolerance to Thyroid Antigens
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
description: >-
Weakened vitamin D-dependent immunoregulation is proposed to lower the
threshold for loss of tolerance to thyroid antigens, though the causal
direction is not established.
- name: Hepatitis C Virus-Associated Thyroid Immune Activation
description: >-
The specific virus with human evidence here is hepatitis C virus (HCV;
chronic HCV infection, MONDO:0005354), which is associated with thyroid
autoimmunity and hypothyroidism. Molecular mimicry between viral and thyroid
antigens and bystander activation of autoreactive lymphocytes are the usual
mechanistic proposals, but the cited evidence is an epidemiological
association, and interferon-based antiviral therapy for HCV is itself
thyrotoxic, which confounds it. This HCV-associated immune-activation state is
the intermediate node between the HCV-infection exposure and the loss of
tolerance.
role: trigger
biological_scale: CELLULAR
biological_processes:
- preferred_term: Defense response to virus
term:
id: GO:0051607
label: defense response to virus
evidence:
- reference: PMID:32107168
reference_title: "Graves' disease: Epidemiology, genetic and environmental risk factors and viruses."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Many studies showed that HCV is associated with thyroid autoimmunity and hypothyroidism, in patients with chronic HCV hepatitis (CHC); a significant link has been shown also between HCV-related mixed cryoglobulinemia and risk for GD."
explanation: >-
Reports the epidemiological association of chronic HCV infection with
thyroid autoimmunity and hypothyroidism, the observation behind this
HCV-associated immune-activation state.
notes: >-
The evidence here is specific to hepatitis C virus. Other viruses (EBV,
HTLV-1, parvovirus B19, enteroviruses, and SARS-CoV-2) have been proposed as
thyroid-autoimmunity triggers but are not substantiated in the cited source
and so are not asserted as nodes. IFN-alpha therapy for chronic HCV is itself
associated with thyroid dysfunction, confounding the HCV-autoimmunity
association.
downstream:
- target: Loss of Immune Tolerance to Thyroid Antigens
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
intermediate_mechanisms:
- Proposed molecular mimicry between viral and thyroid antigens and bystander lymphocyte activation
description: >-
Antiviral immune activation is proposed to break tolerance to thyroid
antigens via molecular mimicry or bystander activation, a mechanism not
established by the cited association.
- name: Loss of Immune Tolerance to Thyroid Antigens
description: >
Susceptibility variants in T-cell regulatory and immune-checkpoint genes
(HLA class II, CTLA4, PTPN22, LAG3) act together with environmental triggers
(iodine excess, selenium/vitamin D status, viral infection) to break
self-tolerance to thyroid peroxidase and thyroglobulin, the initiating lesion
that licenses autoreactive T- and B-cell responses against the thyroid. A
rare LAG3 start-codon variant that lowers the inhibitory checkpoint LAG-3
exemplifies how impaired T-cell down-regulation predisposes to autoimmune
thyroid disease.
role: trigger
genes:
- preferred_term: CTLA4
term:
id: hgnc:2505
label: CTLA4
- preferred_term: PTPN22
term:
id: hgnc:9652
label: PTPN22
- preferred_term: LAG3
term:
id: hgnc:6476
label: LAG3
evidence:
- reference: PMID:38982041
reference_title: "Start codon variant in LAG3 is associated with decreased LAG-3 expression and increased risk of autoimmune thyroid disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Multiomics analysis yields 235 candidate genes outside the MHC-region and the findings highlight the importance of genes involved in T-cell regulation."
explanation: A large AITD GWAS meta-analysis localizes susceptibility to T-cell regulatory genes, supporting loss of T-cell tolerance as the initiating mechanism.
- reference: PMID:42631765
reference_title: "Exosome in Hashimoto's thyroiditis: from pathogenesis to diagnostic and therapeutic potential."
supports: SUPPORT
quote_role: REVIEW_SYNTHESIS
evidence_source: IN_VITRO
snippet: "exosomal HSP60 released from IFN‑γ-stimulated thyroid follicular cells acts as an autoantigen cross‑reacting with TPO and TG, promoting thyrocyte injury through antigen-antibody interactions"
explanation: >-
Identifies exosomal HSP60 from inflamed thyroid follicular cells as a cross-reactive autoantigen that mimics TPO and thyroglobulin epitopes, directly driving the loss of tolerance to thyroid self-antigens.
downstream:
- target: Thyrocyte Antigen Presentation
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Autoreactive T helper cell priming against TPO/Tg
description: >
Breakdown of tolerance permits autoreactive T cells and an interferon-rich
milieu that drives thyroid follicular cells to present antigen.
- target: Lymphocytic Infiltration
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Autoreactive lymphocyte activation and thyroid homing
description: >
Loss of tolerance licenses autoreactive T and B lymphocytes that traffic
into and accumulate within the thyroid gland.
- target: Th17/Treg Imbalance
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Skewed CD4 T helper differentiation away from Foxp3 regulatory commitment
description: >-
Escape from regulatory control shifts the CD4 compartment toward the
IL-17-producing effector program, so the Th17/Treg set point moves with
the loss of tolerance rather than independently of it.
- name: Th17/Treg Imbalance
description: >-
The CD4 T helper compartment in Hashimoto's thyroiditis is shifted away
from Foxp3 regulatory commitment and toward the RORgt-driven,
IL-17-producing Th17 program. Regulatory T cell frequency, Foxp3
transcript, and the Treg/Th17 ratio are all lower in patients, IL-17A is
higher, and the ratio tracks inversely with thyroid autoantibody titres and
TSH. IL-17 signalling in turn raises IL-6, CXCL10 and ICAM-1, feeding the
intrathyroidal infiltrate. Whether this imbalance is an upstream initiator
or a parallel feature of established disease is not settled: the human data
are cross-sectional, and the claim that Th17 predominance precedes
Th1-mediated destruction is a review-level synthesis with no longitudinal
human series behind it (see notes).
role: amplifier
biological_scale: CELLULAR
cell_types:
- preferred_term: T-helper 17 cell
term:
id: CL:0000899
label: T-helper 17 cell
- preferred_term: Regulatory T cell
term:
id: CL:0000815
label: regulatory T cell
biological_processes:
- preferred_term: T-helper 17 cell differentiation
term:
id: GO:0072539
label: T-helper 17 cell differentiation
modifier: INCREASED
- preferred_term: Regulatory T cell differentiation
term:
id: GO:0045066
label: regulatory T cell differentiation
modifier: DECREASED
evidence:
- reference: PMID:25771887
reference_title: "The possible role of CD4+CD25(high)Foxp3+/CD4+IL-17A+ cell imbalance in the autoimmunity of patients with Hashimoto thyroiditis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We found that the percentage of Treg cells, Foxp3 mRNA levels, and the ratio of Treg/Th17 cells were all significantly lower in HT patients, while Th17 cell percentages and RORgammat mRNA levels were significantly higher."
explanation: >-
Direct human measurement of the two arms of this node in patient
peripheral blood: regulatory frequency and Foxp3 down, Th17 frequency and
RORgt up.
- reference: PMID:25771887
reference_title: "The possible role of CD4+CD25(high)Foxp3+/CD4+IL-17A+ cell imbalance in the autoimmunity of patients with Hashimoto thyroiditis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The ratio of Treg/Th17 cells was negatively correlated with the levels of serum thyroperoxidase antibody, thyroglobulin antibody, and thyrotropin (TSH) in HT patients."
explanation: >-
Ties the magnitude of the imbalance to the serologic and hormonal
severity markers of the disease, which is what makes it a mechanism node
rather than an incidental immunophenotype. The design is cross-sectional,
so it establishes covariation, not direction.
- reference: PMID:41243116
reference_title: "Role of interleukin 17 and T helper cells 17 cells as a new immune target and signalling in the pathogenesis and treatment of autoimmune thyroid diseases."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Serum and tissue IL-17 concentrations correlate positively with TPOAb or TgAb titres and early fibrosis"
explanation: >-
Extends the correlation from circulating cell frequencies to IL-17
protein in serum and in thyroid tissue, and links it to early fibrosis.
- reference: PMID:41243116
reference_title: "Role of interleukin 17 and T helper cells 17 cells as a new immune target and signalling in the pathogenesis and treatment of autoimmune thyroid diseases."
supports: SUPPORT
evidence_source: OTHER
snippet: "Th17 predominance precedes Th1-mediated tissue destruction"
explanation: >-
The temporal ordering that would make this node an initiator rather than
a correlate. Graded OTHER because it is a synthesis across the reviewed
human, animal and preclinical literature rather than a result of any one
study design, and no longitudinal human series is cited for it. Recorded
here so the claim is visible with its provenance instead of being
asserted as established.
- reference: PMID:42631765
reference_title: "Exosome in Hashimoto's thyroiditis: from pathogenesis to diagnostic and therapeutic potential."
supports: SUPPORT
quote_role: REVIEW_SYNTHESIS
evidence_source: IN_VITRO
snippet: "T‑cell-derived exosomes enriched in miR‑142‑3p impair regulatory T‑cell function and exacerbate thyrocyte destruction by suppressing RAC1 and inhibiting ERK1/2 signaling"
explanation: >-
Identifies a molecular mechanism by which T-cell-derived exosomes with miR-142-3p directly suppress Treg function through RAC1/ERK1/2 inhibition, contributing to the Th17/Treg imbalance and thyrocyte destruction.
notes: >-
Added from the 2026 openscientist hypothesis-search report, whose executive
judgment calls the Th17/Treg axis an established upstream initiator. That
strength is not supported: the human evidence is cross-sectional and the
precedence claim rests on one 2025 review, while the report's own knowledge
gaps concede that the transition from Th17/Treg imbalance to Th1-mediated
destruction lacks longitudinal human evidence. The node is therefore
curated as an amplifier with a review-level precedence claim, not as the
initiating lesion.
downstream:
- target: Lymphocytic Infiltration
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- IL-17-driven IL-6, CXCL10 and ICAM-1 expression in the thyroid
description: >-
IL-17 signalling through IL-17RA raises chemokine and adhesion-molecule
expression in the gland, amplifying recruitment and retention of the
intrathyroidal lymphocytic infiltrate.
evidence:
- reference: PMID:41243116
reference_title: "Role of interleukin 17 and T helper cells 17 cells as a new immune target and signalling in the pathogenesis and treatment of autoimmune thyroid diseases."
supports: SUPPORT
evidence_source: OTHER
snippet: "IL-17/IL-17RA signalling enhances the expression of IL-6, chemokine CXC ligand 10, and intercellular cell adhesion molecule-1, thereby amplifying thyroid inflammation."
explanation: >-
Names the chemokine and adhesion-molecule intermediates through which
the Th17 arm amplifies thyroid inflammation. Review-level synthesis, so
graded OTHER.
- name: Thyrocyte Antigen Presentation
description: >
Under interferon-gamma and TNF-alpha exposure, thyroid follicular cells
aberrantly upregulate MHC class II together with the invariant chain CD74 and
its ligand MIF, becoming non-professional antigen-presenting cells. This
amplifies local antigen presentation and ligand-receptor cross-talk with
infiltrating immune cells, sustaining and propagating the intrathyroidal
autoimmune response.
role: amplifier
cell_types:
- preferred_term: Thyroid Follicular Cell
term:
id: CL:0002258
label: thyroid follicular cell
biological_processes:
- preferred_term: Antigen presentation via MHC class II
term:
id: GO:0002495
label: antigen processing and presentation of peptide antigen via MHC class II
modifier: INCREASED
evidence:
- reference: PMID:39003267
reference_title: "Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We identify damaged antigen-presenting TFCs with upregulated CD74 and MIF expression in thyroid samples from AITD patients."
explanation: Spatial transcriptomics shows thyroid follicular cells act as antigen-presenting cells via CD74/MIF upregulation, driving local autoimmunity.
images:
- Hashimotos_Thyroiditis-deep-research-falcon_artifacts/image-1.png
downstream:
- target: Lymphocytic Infiltration
causal_link_type: DIRECT
description: >
Thyrocyte antigen presentation and chemokine expression recruit and
activate infiltrating lymphocytes within the gland.
- name: Autoimmune Thyroid Destruction
description: >
T cell-mediated and antibody-mediated destruction of thyroid follicular
cells leads to progressive loss of thyroid function. Anti-thyroid
peroxidase (anti-TPO) and anti-thyroglobulin antibodies are characteristic.
cell_types:
- preferred_term: Thyroid Epithelial Cell
term:
id: CL:0002257
label: epithelial cell of thyroid gland
- preferred_term: T Helper Cell
term:
id: CL:0000492
label: CD4-positive helper T cell
biological_processes:
- preferred_term: Autoimmune Response
term:
id: GO:0002460
label: adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
evidence:
- reference: PMID:39003267
reference_title: "Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We identify damaged antigen-presenting TFCs with upregulated CD74 and MIF expression in thyroid samples from AITD patients."
explanation: Spatial transcriptomics demonstrates that thyroid follicular cells actively participate in autoimmune destruction by presenting antigens via CD74/MIF upregulation.
- reference: PMID:38731922
reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
explanation: Confirms the characteristic antibody profile and lymphocytic infiltration pattern in Hashimoto's thyroiditis.
- reference: PMID:40535343
reference_title: "Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Through this review, we aim to establish mechanistic connections between ICI pharmacodynamics and thyroid tissue immunopathology."
explanation: ICI-induced thyroiditis provides a mechanistic model that mirrors the autoimmune destruction seen in spontaneous Hashimoto's thyroiditis.
- reference: PMID:37445704
reference_title: "RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies."
supports: SUPPORT
directness: INDIRECT
evidence_source: MODEL_ORGANISM
snippet: "Compared to previously published datasets of interleukin-1beta and interferon gamma-treated human thyroid cells, apoptosis pathways were similarly activated."
explanation: >-
INDIRECT because the measurement is thyroid transcriptome in an anti-PD-1
treated murine lung-cancer model, not Hashimoto tissue, so it reaches this
node through the shared cytokine-driven apoptosis step rather than
directly. Read with the caveat below: the same comparison found marked
differences in pathway enrichment and in predicted upstream regulators,
and the authors conclude that checkpoint-inhibitor thyroid disease is a
distinct form of immune thyroid disease. Convergence is on the apoptosis
arm only.
notes: >-
On the immune-checkpoint-inhibitor parallel: the 2026 openscientist
hypothesis-search report presents it as validation of this node "via the
exact pathways described in the canonical model". The transcriptomic study
it cites (PMID:37445704) does not support that reading. Apoptosis pathways
were similarly activated relative to interleukin 1 beta and interferon
gamma treated human thyroid cells, but the authors' own conclusion is that
checkpoint-inhibitor thyroid disease represents a novel form of immune
thyroid disease with distinct underlying pathways and upstream regulators.
The parallel is real but partial, and it is drawn from a murine model. The
clinical arm is stronger and is separately reported: in a prospective
series, 92.9% of PD-1-inhibitor destructive thyroiditis cases were TPOAb or
TgAb positive (PMID:39216687).
downstream:
- target: Thyroid Hormone Deficiency
causal_link_type: DIRECT
description: >
Progressive cytotoxic and antibody-mediated loss of hormone-producing
follicular cells depletes the gland's capacity to synthesize T3 and T4,
producing thyroid hormone deficiency.
evidence:
- reference: PMID:38731922
reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Due to the progressive destruction of cells, AITD can lead to subclinical or overt hypothyroidism."
explanation: Directly links progressive follicular-cell destruction to the resulting hypothyroid hormone deficit.
- target: Hashitoxicosis
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Release of preformed thyroid hormone from destroyed follicles
description: >
Early inflammatory destruction of follicles can release preformed stored
hormone, producing a transient thyrotoxic (hashitoxicosis) phase before
glandular reserve is exhausted and hypothyroidism supervenes.
evidence:
- reference: PMID:24434360
reference_title: "Hashimoto thyroiditis: clinical and diagnostic criteria."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "at presentation patients can be euthyroid or even hyperthyroid"
explanation: Supports a transient hyperthyroid presentation arising from destructive release of stored hormone.
- name: Lymphocytic Infiltration
description: >
Dense lymphocytic infiltration of the thyroid gland with germinal
center formation. CD4+ T cells, CD8+ T cells, and B cells accumulate
in the thyroid parenchyma.
biological_processes:
- preferred_term: Inflammatory response
term:
id: GO:0006954
label: inflammatory response
- preferred_term: Adaptive immune response
term:
id: GO:0002250
label: adaptive immune response
- preferred_term: Intrathyroidal germinal centre formation
term:
id: GO:0002467
label: germinal center formation
modifier: INCREASED
cell_types:
- preferred_term: CD4-positive helper T cell
term:
id: CL:0000492
label: CD4-positive helper T cell
- preferred_term: CD8-positive, alpha-beta T cell
term:
id: CL:0000625
label: CD8-positive, alpha-beta T cell
- preferred_term: B Cell
term:
id: CL:0000236
label: B cell
evidence:
- reference: PMID:38731922
reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
explanation: Lymphocytic infiltration is a defining histological feature of Hashimoto's thyroiditis.
- reference: PMID:39003267
reference_title: "Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Here, we use spatial transcriptomics to explore the molecular architecture, heterogeneity and location of different cells present in the thyroid tissue, including thyroid follicular cells (TFCs), stromal cells such as fibroblasts, endothelial cells, and thyroid infiltrating lymphocytes."
explanation: Spatial analysis confirms the presence and organization of infiltrating lymphocytes in the thyroid microenvironment.
- reference: PMID:11549579
reference_title: "Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Intrathyroidal LFs were microanatomically very similar to canonical LFs, ie, they had well-developed germinal centers with mantle, light, and dark zones and each of these zones contained B and T lymphocytes, follicular dendritic and interdigitating dendritic cells with typical phenotypes."
explanation: >-
Grounds the germinal-centre component of this node. Direct comparison
against tonsil and lymph node follicles shows the intrathyroidal lymphoid
follicles are structurally complete germinal centres, not merely dense
aggregates, and the same study found most of them bind thyroglobulin and
thyroperoxidase, so they are committed to thyroid self-antigen.
- reference: PMID:11549579
reference_title: "Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Unexpected high levels of RAG expression suggested that receptor revision occurs in intrathyroidal LFs and may contribute to generate high-affinity thyroid autoantibodies."
explanation: >-
Adds the functional consequence: RAG1/RAG2 re-expression inside the gland
implies receptor revision happens locally, so the infiltrate is a site of
autoantibody affinity maturation rather than only a destination for cells
primed elsewhere. Note the source phrases receptor revision as suggested
by the RAG expression, not demonstrated.
downstream:
- target: Autoimmune Thyroid Destruction
causal_link_type: DIRECT
description: >
Infiltrating cytotoxic T cells, autoantibody-producing B/plasma cells, and
inflammatory macrophages execute follicular-cell killing.
evidence:
- reference: PMID:38731922
reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
explanation: Links the lymphocytic infiltrate and thyroid autoantibodies to the destructive autoimmune process.
- target: Goiter
causal_link_type: DIRECT
description: >
Dense inflammatory infiltration and lymphoid-follicle formation enlarge the
gland, producing the characteristic diffuse goiter.
- target: Cytokine-Sensitized Fas-Mediated Thyrocyte Apoptosis
causal_link_type: DIRECT
description: >-
The infiltrating lymphocytes are the effector killers of the follicular
cells, and the cytokines they release are what render otherwise resistant
thyrocytes killable through Fas.
- name: Cytokine-Sensitized Fas-Mediated Thyrocyte Apoptosis
description: >-
Normal thyroid follicular cells express Fas but resist Fas-mediated
apoptosis: signalling is blocked downstream of the proximal caspases.
Interferon gamma together with interleukin 1 beta lifts that block by
raising surface Fas, procaspases 7, 8 and 10, and the proapoptotic BH3
protein Bid, so that Fas ligation then cleaves caspases 7 and 3, engages
mitochondria, and kills the cell. This cytokine gate is the reason
destruction is confined to the inflamed gland. The killing is executed by
the intrathyroidal lymphocytes rather than by the thyrocytes themselves,
and it proceeds without perforin. It is not exclusively a Fas/FasL process:
ex vivo killing is only partially blocked by disrupting Fas/FasL and a
caspase-independent route appears to coexist.
role: effector
biological_scale: CELLULAR
cell_types:
- preferred_term: Thyroid Follicular Cell
term:
id: CL:0002258
label: thyroid follicular cell
biological_processes:
- preferred_term: Fas death-receptor apoptotic signalling in thyrocytes
term:
id: GO:0008625
label: extrinsic apoptotic signaling pathway via death domain receptors
modifier: INCREASED
evidence:
- reference: PMID:15563545
reference_title: "Induction and regulation of Fas-mediated apoptosis in human thyroid epithelial cells."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Normal thyroid cells are resistant to Fas-mediated apoptosis in vitro but can be sensitized by the unique combination of interferon-gamma and IL-1beta cytokines."
explanation: >-
Establishes the cytokine gate that defines this node in primary human
thyroid cells: resistance at baseline, sensitivity only after interferon
gamma plus interleukin 1 beta.
- reference: PMID:11716038
reference_title: "Thyrocyte targets and effectors of autoimmunity: a role for death receptors?"
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "In Hashimoto's thyroiditis, thyrocytes were poorly functional while lymphocytes were able to operate as effectors."
explanation: >-
Identifies which cell does the killing. In Hashimoto glands only the
lymphocytes killed Fas-expressing targets, which argues against the
thyrocyte fratricide reading of Fas/FasL and places the effector role on
the infiltrate, consistent with the upstream edge from Lymphocytic
Infiltration.
- reference: PMID:11716038
reference_title: "Thyrocyte targets and effectors of autoimmunity: a role for death receptors?"
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Cell death was only partially dependent on Fas/Fas ligand but it was trypsin-sensitive. Blocking perforin did not affect Fas-expressing target killing while caspase inhibitors had a consistent although limited effect."
explanation: >-
Bounds the claim in both directions. Perforin blockade does nothing, so
the pathway is perforin-independent as curated; but Fas/FasL disruption
only partially blocks killing and caspase inhibition has limited effect,
so a coexisting caspase-independent route is implied and Fas/FasL cannot
be called the sole or fully dominant mechanism.
notes: >-
Added from the 2026 openscientist hypothesis-search report, which describes
Fas/FasL apoptosis as the confirmed dominant killing pathway. Perforin
independence is supported; dominance is not. The report's supporting
citations are a 1997 one-paragraph commentary hedged to "may determine"
(PMID:9274519) and PMID:11716038, which actually reports only partial
Fas/FasL dependence alongside a probable caspase-independent mechanism. The
node is therefore curated as a well-evidenced, cytokine-gated,
perforin-independent killing route, not as the exclusive one.
downstream:
- target: Autoimmune Thyroid Destruction
causal_link_type: DIRECT
description: >-
Cytokine-sensitized Fas ligation kills follicular cells, which is the
cellular execution step of the destructive process.
- name: NF-κB-IL-6 Signaling Pathway Activation
description: >
Genetic regulation of NF-κB and IL-6 signaling modulates the autoimmune
response in Hashimoto's thyroiditis. CCDC77 and SLC45A3 are novel genetic
modifiers that regulate NF-κB pathway activation and IL-6 production. CCDC77
acts as a protective regulator (knockdown exacerbates thyroid damage),
while SLC45A3 acts as a disease-promoting factor (knockdown alleviates thyroiditis).
The NF-κB-IL-6 axis modulates immune cell activation and thyroid-targeted autoimmunity.
role: amplifier
genes:
- preferred_term: CCDC77
term:
id: hgnc:28203
label: CCDC77
- preferred_term: SLC45A3
term:
id: hgnc:8642
label: SLC45A3
biological_processes:
- preferred_term: NF-κB signaling pathway
term:
id: GO:0007249
label: canonical NF-kappaB signal transduction
- preferred_term: Inflammatory response
term:
id: GO:0006954
label: inflammatory response
cell_types:
- preferred_term: Macrophage
term:
id: CL:0000235
label: macrophage
- preferred_term: Dendritic cell
term:
id: CL:0000451
label: dendritic cell
evidence:
- reference: PMID:42283571
reference_title: "CCDC77 and SLC45A3 mediate the genetic mechanism of Hashimoto's thyroiditis through IL-6."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "MR analysis identified CCDC77 and SLC45A3 as key genes associated with both IL-6 and HT."
explanation: Two-sample Mendelian randomization using human eQTL/GWAS data identified CCDC77 and SLC45A3 as IL-6-linked genes associated with Hashimoto's thyroiditis.
- reference: PMID:42283571
reference_title: "CCDC77 and SLC45A3 mediate the genetic mechanism of Hashimoto's thyroiditis through IL-6."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "In vivo experiments showed that knockdown of CCDC77 exacerbated thyroid damage, increased serum anti-thyroperoxidase antibody (TPOAb), anti-thyroglobulin antibody (TGAb), and IL-6 levels, while reduced free triiodothyronine (FT3) and free thyroxine (FT4). Conversely, SLC45A3 knockdown alleviated thyroiditis, reduced antibody levels, and improved thyroid function."
explanation: In vivo validation in NOD mice demonstrates that CCDC77 and SLC45A3 regulate HT progression through the NF-κB-IL-6 signaling axis; CCDC77 is a protective modulator while SLC45A3 is disease-promoting.
- reference: PMID:42631765
reference_title: "Exosome in Hashimoto's thyroiditis: from pathogenesis to diagnostic and therapeutic potential."
supports: SUPPORT
quote_role: REVIEW_SYNTHESIS
evidence_source: IN_VITRO
snippet: "Patient‑derived exosomes containing elevated TPO and MHC‑II activate dendritic cells via TLR2/3 and NF‑κB pathways, driving Th1/Th17 polarization while suppressing Treg differentiation"
explanation: >-
Identifies patient-derived exosomes as an upstream activator of the NF-κB
signaling this node describes, acting on dendritic cells through TLR2/3.
It adds a route to NF-κB pathway activation that is independent of the
CCDC77/SLC45A3 genetic modifiers curated on the same node, and places
dendritic cells alongside macrophages as a cell type in which the axis
operates.
downstream:
- target: Lymphocytic Infiltration
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- IL-6-driven Th17 differentiation and immune-cell activation
description: >
Genetic modulation of the NF-κB-IL-6 axis tunes immune-cell activation and
recruitment, amplifying the intrathyroidal lymphocytic infiltrate.
evidence:
- reference: PMID:42283571
reference_title: "CCDC77 and SLC45A3 mediate the genetic mechanism of Hashimoto's thyroiditis through IL-6."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "In vivo experiments showed that knockdown of CCDC77 exacerbated thyroid damage, increased serum anti-thyroperoxidase antibody (TPOAb), anti-thyroglobulin antibody (TGAb), and IL-6 levels, while reduced free triiodothyronine (FT3) and free thyroxine (FT4). Conversely, SLC45A3 knockdown alleviated thyroiditis, reduced antibody levels, and improved thyroid function."
explanation: NOD-mouse knockdown of NF-κB-IL-6 axis genes changes thyroid damage and antibody levels, linking this signaling node to the autoimmune infiltrate.
- name: Thyroid Hormone Deficiency
conforms_to: "hypothyroidism_thyroid_hormone_deficiency#Impaired Thyroid Hormone Synthesis"
description: >
Progressive destruction of thyroid tissue leads to decreased
production of T3 and T4, resulting in hypothyroidism with elevated
TSH through negative feedback.
biological_processes:
- preferred_term: Thyroid Hormone Synthesis
term:
id: GO:0006590
label: thyroid hormone generation
modifier: DECREASED
evidence:
- reference: PMID:38731922
reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Due to the progressive destruction of cells, AITD can lead to subclinical or overt hypothyroidism."
explanation: Progressive thyroid destruction in Hashimoto's thyroiditis results in hypothyroidism through loss of hormone-producing cells.
downstream:
- target: Hypothyroidism
causal_link_type: DIRECT
description: >
Insufficient T3/T4 output with compensatory TSH elevation manifests
clinically as primary hypothyroidism.
evidence:
- reference: PMID:32805423
reference_title: "Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "developing a primary hypothyroidism"
explanation: The hormone-synthesis deficit produces clinical primary hypothyroidism.
phenotypes:
- name: Vitamin D Deficiency
category: Nutritional
description: >-
Decreased circulating vitamin D (HP:0100512) modeled here as an upstream,
modifiable risk state rather than a manifestation of the thyroid disease. As
a deficiency state it is a convergence point reachable by several routes -
reduced dietary intake, reduced cutaneous (UVB) synthesis, or impaired
intestinal absorption (relevant in HT given its comorbidity with autoimmune
gastritis and celiac disease). Only the intake/synthesis route is currently
wired in as an evidenced edge. It is consistently observed at lower levels in
HT patients; the causal direction is uncertain (see notes).
phenotype_term:
preferred_term: Vitamin D deficiency
term:
id: HP:0100512
label: Decreased circulating vitamin D concentration
evidence:
- reference: PMID:38542128
reference_title: "Autoimmune Thyroiditis and Vitamin D."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "There is extensive literature confirming that vitamin D levels are significantly lower in HT patients compared to healthy people."
explanation: >-
Grounds the vitamin D-deficiency state as a finding associated with HT.
notes: >-
HP:0100512 is bound here as an upstream risk state, not a manifestation:
because this phenotype has a sequelae edge into a pathophysiology node, the
KGX/HPOA exporters export it as a direction-neutral
`MONDO:0007699 biolink:associated_with HP:0100512` rather than
`has_phenotype`. (This supersedes the earlier workaround of binding
MONDO:0100471 to dodge the has_phenotype inversion; the direction-aware
exporter makes the HP binding correct.) The association is cross-sectional
and may be bidirectional; part of the nutritional-risk literature
(PMID:28290237) attributes low vitamin D to the autoimmune process itself,
including vitamin D receptor dysfunction.
sequelae:
- target: Impaired Vitamin D-Dependent Immune Tolerance
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
description: >-
Vitamin D deficiency is proposed to weaken vitamin D-dependent
immunoregulation; the causal direction is not established.
- name: Selenium Deficiency
category: Nutritional
description: >-
Decreased circulating selenium (HP:0033192) modeled here as an upstream,
modifiable risk state for HT. As a deficiency state it is a convergence point
reachable by reduced dietary intake or impaired intestinal absorption
(relevant in HT given its comorbidity with autoimmune gastritis and celiac
disease); only the intake route is currently wired in as an evidenced edge.
Low selenium status raises the incidence of thyroid autoantibody
seroconversion.
phenotype_term:
preferred_term: Selenium deficiency
term:
id: HP:0033192
label: Decreased circulating selenium concentration
evidence:
- reference: PMID:35789269
reference_title: "Increased Incidence of Hashimoto Thyroiditis in Selenium Deficiency: A Prospective 6-Year Cohort Study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The data indicate an increased incidence of TPO-Ab seroconversion with low Se supply and support the hypothesis that Se deficiency contributes to HT as a modifiable risk factor."
explanation: >-
Prospective cohort evidence grounding selenium deficiency as a modifiable
risk state associated with onset of thyroid autoimmunity.
notes: >-
HP:0033192 is bound here as an upstream risk state, not a manifestation. The
KGX/HPOA exporters detect that (this phenotype has a sequelae edge into a
pathophysiology node) and export it as a direction-neutral
`MONDO:0007699 biolink:associated_with HP:0033192` rather than
`has_phenotype`, so the export does not invert the cited prospective cohort
in which low selenium supply *precedes* TPO-Ab seroconversion. MONDO has no
human selenium-deficiency class (MONDO:1017720 is explicitly
non-human-animal, MONDO:0000241 Keshan disease is a distinct cardiomyopathy),
so HP is the only grounding available - and, with the direction-aware
exporter, the correct one.
sequelae:
- target: Thyroidal Oxidative Stress from Selenoprotein Insufficiency
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Loss of selenoprotein glutathione-peroxidase antioxidant capacity
description: >-
Selenium deficiency limits selenoprotein glutathione peroxidases, driving
thyroidal oxidative stress.
- name: Fatigue
category: Systemic
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
evidence:
- reference: PMID:35235282
reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
explanation: Hashimoto-associated hypothyroidism commonly presents with fatigue.
- name: Weight Gain
category: Metabolic
frequency: FREQUENT
phenotype_term:
preferred_term: Weight Gain
term:
id: HP:0004324
label: Increased body weight
evidence:
- reference: PMID:35235282
reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
explanation: Weight gain is a common hypothyroid symptom in Hashimoto's thyroiditis.
- name: Constipation
category: Gastrointestinal
frequency: FREQUENT
phenotype_term:
preferred_term: Constipation
term:
id: HP:0002019
label: Constipation
evidence:
- reference: PMID:35235282
reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
explanation: Constipation is a recognized symptom in hypothyroid states.
- name: Dry Skin
category: Dermatological
frequency: FREQUENT
phenotype_term:
preferred_term: Dry Skin
term:
id: HP:0000958
label: Dry skin
evidence:
- reference: PMID:35235282
reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
explanation: Dry skin is a common dermatologic manifestation of hypothyroidism.
- name: Cold Intolerance
category: Systemic
frequency: FREQUENT
phenotype_term:
preferred_term: Cold Intolerance
term:
id: HP:6000855
label: Cold intolerance
evidence:
- reference: PMID:35235282
reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Signs and symptoms include fatigue, weight gain, dry skin, constipation, and cold intolerance."
explanation: Cold intolerance is a common symptom of hypothyroidism in Hashimoto's thyroiditis.
- name: Goiter
category: Endocrine
frequency: FREQUENT
phenotype_term:
preferred_term: Goiter
term:
id: HP:0000853
label: Goiter
evidence:
- reference: PMID:38731922
reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
explanation: Goiter develops due to lymphocytic infiltration and inflammatory enlargement of the thyroid gland.
- name: Depression
category: Psychiatric
notes: >-
Frequency band deliberately omitted: the only cited source lists depression
among the "most common presenting symptoms", which conflicts with the
previously curated OCCASIONAL (5-29%) band and provides no quantitative
estimate. Per the frequency-evidence guidelines, no band is asserted.
phenotype_term:
preferred_term: Depression
term:
id: HP:0000716
label: Depression
evidence:
- reference: PMID:23744563
reference_title: "Selenium supplementation for Hashimoto's thyroiditis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The most common presenting symptoms may include anxiety, negative mood, depression, dry skin, cold intolerance, puffy eyes, muscle cramps and fatigue, deep voice, constipation, slow thinking and poor memory."
explanation: Depression is reported among common presenting symptoms in Hashimoto's thyroiditis.
- name: "Hypothyroidism"
category: Endocrine
description: "Autoimmune destruction of the thyroid gland in Hashimoto thyroiditis produces primary hypothyroidism."
phenotype_term:
preferred_term: "Hypothyroidism"
term:
id: HP:0000821
label: "Hypothyroidism"
evidence:
- reference: PMID:32805423
reference_title: "Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "developing a primary hypothyroidism"
explanation: "This review states Hashimoto thyroiditis develops a primary hypothyroidism."
sequelae:
- target: Fatigue
- target: Weight Gain
- target: Cold Intolerance
- target: Dry Skin
- target: Constipation
- target: Depression
- name: "Hashitoxicosis"
category: Endocrine
description: "A transient hyperthyroid phase (Hashitoxicosis) can occur at presentation of Hashimoto thyroiditis before evolution to hypothyroidism."
phenotype_term:
preferred_term: "Hashitoxicosis (transient hyperthyroidism)"
term:
id: HP:0000836
label: "Hyperthyroidism"
evidence:
- reference: PMID:24434360
reference_title: "Hashimoto thyroiditis: clinical and diagnostic criteria."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "at presentation patients can be euthyroid or even hyperthyroid"
explanation: "This clinical-criteria review notes patients may be hyperthyroid at presentation of Hashimoto thyroiditis."
biochemical:
- name: TSH
presence: Elevated
context: Primary hypothyroidism
evidence:
- reference: PMID:35235282
reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Overt hypothyroidism occurs when a patient has an elevated TSH level and a low free T4 level with symptoms of hypothyroidism."
explanation: Elevated TSH is a core biochemical feature of overt hypothyroidism in Hashimoto's disease.
readouts:
- target: Thyroid Hormone Deficiency
relationship: READOUT_OF
direction: POSITIVE
endpoint_context: DIAGNOSTIC
interpretation: >
Compensatory TSH elevation is the biochemical hallmark that reports the
thyroid hormone synthesis deficit in primary hypothyroidism.
- name: Free T4
presence: Decreased
context: Overt hypothyroidism
evidence:
- reference: PMID:35235282
reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Overt hypothyroidism occurs when a patient has an elevated TSH level and a low free T4 level with symptoms of hypothyroidism."
explanation: Low free T4 defines overt hypothyroidism and supports this biochemical pattern.
readouts:
- target: Thyroid Hormone Deficiency
relationship: READOUT_OF
direction: NEGATIVE
endpoint_context: DIAGNOSTIC
interpretation: >
Low free T4 directly measures the reduced thyroid hormone output; lower
values track with more severe hormone deficiency.
- name: Anti-TPO Antibodies
presence: Elevated
context: Diagnostic marker
evidence:
- reference: PMID:38731922
reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
explanation: Supports anti-TPO positivity as a characteristic diagnostic marker in HT.
readouts:
- target: Autoimmune Thyroid Destruction
relationship: READOUT_OF
direction: PRESENT_ABSENT
endpoint_context: DIAGNOSTIC
interpretation: >
Anti-TPO positivity reports the ongoing autoimmune attack on thyroid
peroxidase and is the principal serologic marker of the destructive process.
- name: Anti-Thyroglobulin Antibodies
presence: Elevated
context: Present in majority of patients
evidence:
- reference: PMID:38731922
reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
explanation: Supports elevated anti-thyroglobulin antibodies in HT.
readouts:
- target: Autoimmune Thyroid Destruction
relationship: READOUT_OF
direction: PRESENT_ABSENT
endpoint_context: DIAGNOSTIC
interpretation: >
Anti-thyroglobulin positivity reflects humoral autoimmunity against
thyroglobulin accompanying follicular destruction.
- name: Circulating Exosomal Proteomic Signature
presence: Elevated
context: >-
Emerging, not clinically validated. Reported as a distinct exosomal protein
profile in HT, with HGFL, FAK1 and PTN12 among the immunomodulatory proteins
increased relative to controls.
evidence:
- reference: PMID:42631765
reference_title: "Exosome in Hashimoto's thyroiditis: from pathogenesis to diagnostic and therapeutic potential."
supports: SUPPORT
quote_role: REVIEW_SYNTHESIS
evidence_source: HUMAN_CLINICAL
snippet: "Proteomic studies further reveal distinct exosomal signatures in HT, including increased immunomodulatory proteins such as HGFL, FAK1, and PTN12."
explanation: >-
Records the proteomic half of the cited review: circulating exosomes in HT
carry a protein profile distinguishable from controls. The quoted sentence
is the review's synthesis of patient-sample proteomics it did not itself
perform, so it is graded HUMAN_CLINICAL for the studies described and
marked REVIEW_SYNTHESIS for where the sentence sits.
notes: >-
Deliberately carries no readouts block and no biomarker_term. The source is a
narrative review reporting that a signature exists; it gives no sensitivity,
specificity, cut-off, assay, or replication cohort, so there is nothing to
support a diagnostic readout claim against a pathophysiology node. Recorded
here as an emerging marker so the concept is visible with its provenance
rather than dropped, and so a later primary-source pass has somewhere to
attach. The three named proteins are left unbound: HGFL, FAK1 and PTN12 are
the review's own shorthand rather than HGNC symbols (HGF-like protein / MST1,
PTK2, PTPN12), and binding them would mean resolving that mapping from a
source that does not state it.
genetic:
- name: HLA-DR3
association: Risk Factor
evidence:
- reference: PMID:26235382
reference_title: "Immunogenetics of autoimmune thyroid diseases: A comprehensive review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "AITD susceptibility genes can be categorized as either thyroid specific (Tg, TSHR) or immune-modulating (FOXP3, CD25, CD40, CTLA-4, HLA), with HLA-DR3 carrying the highest risk."
explanation: HLA-DR3 is identified as a major immune-genetic risk factor in autoimmune thyroid disease, including HT.
- name: HLA-DR4
association: Risk Factor
evidence:
- reference: PMID:29174716
reference_title: "Interaction of HLA-DRB1* alleles and CTLA4 (+49 AG) gene polymorphism in Autoimmune Thyroid Disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "'DRB1*04+GG' (PL: p=0.003; HT: p=0.008)"
explanation: HLA-DRB1*04 contributes to susceptibility in combination with CTLA4 risk genotype in HT cohorts.
- name: CTLA4
association: Risk Factor
relationship_type: SUSCEPTIBILITY
gene_term:
preferred_term: CTLA4
term:
id: hgnc:2505
label: CTLA4
evidence:
- reference: PMID:41498152
reference_title: "CTLA4, PTNP22, and FOXO3A gene variants as genetic biomarkers for co-occurrence of type 1 diabetes and autoimmune thyroid diseases in the Polish population."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "CTLA4 polymorphisms were associated with an elevated risk of a thyroid disease and poorer glycemic control;"
explanation: CTLA4 polymorphisms are associated with increased autoimmune thyroid disease risk.
- name: PTPN22
association: Risk Factor
relationship_type: SUSCEPTIBILITY
gene_term:
preferred_term: PTPN22
term:
id: hgnc:9652
label: PTPN22
evidence:
- reference: PMID:33103521
reference_title: "The Relationship between PTPN22 R620W Polymorphisms and the Susceptibility to Autoimmune Thyroid Diseases: An Updated Meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "This meta-analysis showed that the PTPN22 R620W polymorphism is associated with the risk of GD and HT in the overall study population."
explanation: Meta-analysis supports PTPN22 as a susceptibility locus for Hashimoto's thyroiditis.
- name: LAG3
association: Risk Factor
gene_term:
preferred_term: LAG3
term:
id: hgnc:6476
label: LAG3
evidence:
- reference: PMID:38982041
reference_title: "Start codon variant in LAG3 is associated with decreased LAG-3 expression and increased risk of autoimmune thyroid disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "rs781745126-T reduces mRNA and surface expression of the inhibitory immune checkpoint LAG-3 co-receptor on activated lymphocyte subsets and halves LAG-3 levels in plasma among heterozygotes."
explanation: A rare LAG3 5'-UTR start-codon variant lowers the inhibitory checkpoint LAG-3, unleashing autoreactive lymphocytes and conferring the largest single-variant AITD risk (OR 3.42).
- name: CCDC77
gene_term:
preferred_term: CCDC77
term:
id: hgnc:28203
label: CCDC77
association: Protective
evidence:
- reference: PMID:42283571
reference_title: "CCDC77 and SLC45A3 mediate the genetic mechanism of Hashimoto's thyroiditis through IL-6."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "MR analysis identified CCDC77 and SLC45A3 as key genes associated with both IL-6 and HT."
explanation: Mendelian randomization using eQTL/GWAS data identifies CCDC77 as genetically associated with HT through IL-6.
- reference: PMID:42283571
reference_title: "CCDC77 and SLC45A3 mediate the genetic mechanism of Hashimoto's thyroiditis through IL-6."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "knockdown of CCDC77 exacerbated thyroid damage, increased serum anti-thyroperoxidase antibody (TPOAb), anti-thyroglobulin antibody (TGAb), and IL-6 levels, while reduced free triiodothyronine (FT3) and free thyroxine (FT4)."
explanation: NOD mouse knockdown demonstrates that CCDC77 loss exacerbates thyroid autoimmunity, confirming CCDC77 as protective through NF-κB-IL-6 signaling.
- name: SLC45A3
gene_term:
preferred_term: SLC45A3
term:
id: hgnc:8642
label: SLC45A3
association: Risk Factor
evidence:
- reference: PMID:42283571
reference_title: "CCDC77 and SLC45A3 mediate the genetic mechanism of Hashimoto's thyroiditis through IL-6."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "MR analysis identified CCDC77 and SLC45A3 as key genes associated with both IL-6 and HT."
explanation: Mendelian randomization using eQTL/GWAS data identifies SLC45A3 as genetically associated with HT through IL-6.
- reference: PMID:42283571
reference_title: "CCDC77 and SLC45A3 mediate the genetic mechanism of Hashimoto's thyroiditis through IL-6."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "SLC45A3 knockdown alleviated thyroiditis, reduced antibody levels, and improved thyroid function."
explanation: NOD mouse knockdown shows that SLC45A3 reduction ameliorates thyroid autoimmunity, confirming SLC45A3 as a risk factor via NF-κB-IL-6 axis.
environmental:
- name: Iodine Excess
exposure_term:
preferred_term: excess iodine exposure
modifier: INCREASED
term:
id: ECTO:9000084
label: exposure to iodine
influences_mechanisms:
- target: Thyroglobulin Hyperiodination and Neoantigen Formation
environmental_effect: TRIGGERS
causal_link_type: DIRECT
description: >-
Excess iodine directly raises the iodination of thyroglobulin, and the
more heavily iodinated protein is the more immunogenic one. That is why
iodine supplementation programmes are followed by a rise in autoimmune
thyroiditis. The immunogenic hyperiodinated-Tg state is now the explicit
intermediate node feeding the loss of tolerance.
evidence:
- reference: PMID:28290237
reference_title: "Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Chronic exposure to excess iodine intake induces autoimmune thyroiditis, partly because highly iodinated thyroglobulin (Tg) is more immunogenic."
explanation: >-
States that chronic excess iodine intake induces autoimmune
thyroiditis, partly because highly iodinated thyroglobulin is more
immunogenic, naming the intervening step.
notes: Can trigger or worsen disease
evidence:
- reference: PMID:28290237
reference_title: "Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Chronic exposure to excess iodine intake induces autoimmune thyroiditis, partly because highly iodinated thyroglobulin (Tg) is more immunogenic."
explanation: Excess iodine exposure is associated with autoimmune thyroiditis in HT-focused nutritional risk literature.
- name: Low Dietary Selenium Intake
exposure_term:
preferred_term: low dietary selenium exposure
modifier: DECREASED
term:
id: ECTO:9000950
label: exposure to selenium
influences_mechanisms:
- target: Selenium Deficiency
environmental_effect: TRIGGERS
causal_link_type: DIRECT
description: >-
Low habitual selenium intake is the exposure that produces the systemic
"Selenium Deficiency" state, which in turn drives thyroidal oxidative
stress.
evidence:
- reference: PMID:35789269
reference_title: "Increased Incidence of Hashimoto Thyroiditis in Selenium Deficiency: A Prospective 6-Year Cohort Study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The data indicate an increased incidence of TPO-Ab seroconversion with low Se supply and support the hypothesis that Se deficiency contributes to HT as a modifiable risk factor."
explanation: >-
Links low selenium supply (the dietary exposure) to the
selenium-deficiency state and increased thyroid autoantibody
seroconversion.
notes: May increase risk
evidence:
- reference: PMID:35789269
reference_title: "Increased Incidence of Hashimoto Thyroiditis in Selenium Deficiency: A Prospective 6-Year Cohort Study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The data indicate an increased incidence of TPO-Ab seroconversion with low Se supply and support the hypothesis that Se deficiency contributes to HT as a modifiable risk factor."
explanation: Prospective cohort data support selenium deficiency as a modifiable risk factor for Hashimoto's thyroiditis.
- name: Hepatitis C Virus Infection
exposure_term:
preferred_term: viral exposure
term:
id: ECTO:3000001
label: exposure to virus
influences_mechanisms:
- target: Hepatitis C Virus-Associated Thyroid Immune Activation
environmental_effect: PREDISPOSES
causal_link_type: DIRECT
description: >-
Chronic hepatitis C virus (HCV) infection directly drives the antiviral
immune activation captured by the intermediate node. Molecular mimicry and
bystander activation are the usual proposals for how that then breaks
tolerance, but the cited evidence is an association with chronic hepatitis
C rather than a demonstration of either, and interferon treatment of that
infection is itself thyrotoxic, which confounds the association.
evidence:
- reference: PMID:32107168
reference_title: "Graves' disease: Epidemiology, genetic and environmental risk factors and viruses."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Many studies showed that HCV is associated with thyroid autoimmunity and hypothyroidism, in patients with chronic HCV hepatitis (CHC); a significant link has been shown also between HCV-related mixed cryoglobulinemia and risk for GD."
explanation: >-
Reports that hepatitis C virus is associated with thyroid autoimmunity
and hypothyroidism in patients with chronic infection, an association
rather than a mechanism.
notes: >-
HCV is the specific virus with human evidence; other candidate viruses are
unverified here (see the pathophysiology node notes).
evidence:
- reference: PMID:32107168
reference_title: "Graves' disease: Epidemiology, genetic and environmental risk factors and viruses."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Many studies showed that HCV is associated with thyroid autoimmunity and hypothyroidism, in patients with chronic HCV hepatitis (CHC); a significant link has been shown also between HCV-related mixed cryoglobulinemia and risk for GD."
explanation: Chronic hepatitis C virus infection is associated with thyroid autoimmunity and hypothyroidism.
- name: Low Vitamin D Intake and Cutaneous Synthesis
exposure_term:
preferred_term: low vitamin D exposure
modifier: DECREASED
term:
id: ECTO:9000133
label: exposure to vitamin D
influences_mechanisms:
- target: Vitamin D Deficiency
environmental_effect: PREDISPOSES
causal_link_type: DIRECT
description: >-
Inadequate dietary vitamin D and reduced cutaneous synthesis are the
exposure that produces the systemic vitamin D-deficiency state (the
grounded "Vitamin D Deficiency" state, HP:0100512). This is the weakest
of the risk factors and the most exposed to reverse causation: the cited
finding is that levels are lower in people who already have the disease,
which cross-sectional data cannot separate from chronic illness lowering
vitamin D. Recorded as PREDISPOSES rather than TRIGGERS for that reason,
matching how the HCV edge is qualified.
evidence:
- reference: PMID:38542128
reference_title: "Autoimmune Thyroiditis and Vitamin D."
supports: SUPPORT
directness: INDIRECT
evidence_source: HUMAN_CLINICAL
snippet: "There is extensive literature confirming that vitamin D levels are significantly lower in HT patients compared to healthy people."
explanation: >-
INDIRECT because the snippet supports only half of what this edge
asserts: it establishes that the deficiency state is associated with HT,
but says nothing about dietary intake or cutaneous synthesis as the
route to that state. It is also a cross-sectional comparison, so it does
not establish direction.
notes: >
Low vitamin D status is consistently associated with HT; vitamin D has an
immunomodulatory role promoting immune tolerance, and its deficiency is a
candidate modifiable risk factor.
evidence:
- reference: PMID:38542128
reference_title: "Autoimmune Thyroiditis and Vitamin D."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "There is extensive literature confirming that vitamin D levels are significantly lower in HT patients compared to healthy people."
explanation: A 2024 review confirms vitamin D levels are significantly lower in HT patients, supporting deficiency as an associated environmental risk factor.
treatments:
- name: Levothyroxine
description: >
Thyroid hormone replacement therapy, the mainstay of treatment. It corrects
the hormone deficiency by bypassing the destroyed gland but does not address
the upstream autoimmunity or inflammation.
therapeutic_modality: SMALL_MOLECULE
target_mechanisms:
- target: Thyroid Hormone Deficiency
treatment_effect: BYPASSES
description: >
Exogenous levothyroxine restores circulating T4/T3 and normalizes TSH,
bypassing the hormone-synthesis capacity lost to glandular destruction.
evidence:
- reference: PMID:35235282
reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Management includes thyroid hormone replacement, ideally levothyroxine."
explanation: Levothyroxine replaces the deficient thyroid hormone output.
evidence:
- reference: PMID:35235282
reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Management includes thyroid hormone replacement, ideally levothyroxine."
explanation: Levothyroxine is standard hormone replacement therapy in hypothyroidism due to HT.
- name: Selenium Supplementation
description: >
Adjunctive selenium can lower thyroid autoantibody titers, but a 2024
multicenter double-blind RCT found no quality-of-life benefit over placebo in
LT4-treated autoimmune thyroiditis, illustrating a biomarker-outcome
dissociation.
target_mechanisms:
- target: Autoimmune Thyroid Destruction
treatment_effect: MODULATES
description: >
Selenium lowers TPO antibody titers, a serologic readout of the autoimmune
process, without clearly altering clinical outcome.
evidence:
- reference: PMID:38243784
reference_title: "Selenium Supplementation in Patients with Hashimoto Thyroiditis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In people with HT without THRT, selenium was effective and safe in lowering TSH, TPOAb, and MDA levels."
explanation: Selenium modulates the autoimmune biomarker profile (TPOAb) in HT.
evidence:
- reference: PMID:38243784
reference_title: "Selenium Supplementation in Patients with Hashimoto Thyroiditis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In people with HT without THRT, selenium was effective and safe in lowering TSH, TPOAb, and MDA levels."
explanation: Meta-analysis supports selenium as a potential adjunct in selected HT patients.
- reference: PMID:38215286
reference_title: "Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "no difference in any of the ThyPRO-39 scales was found between the selenium group and the placebo group after 12 months of intervention"
explanation: A 412-patient double-blind RCT found selenium gave no quality-of-life benefit over placebo despite biochemical antibody effects, tempering enthusiasm for routine use.
- name: Vitamin D Supplementation
description: >
Cholecalciferol supplementation in vitamin D-deficient HT patients can lower
thyroid autoantibody titers; evidence is preliminary and further randomized
trials are needed.
target_mechanisms:
- target: Autoimmune Thyroid Destruction
treatment_effect: MODULATES
description: >
Vitamin D's immunomodulatory action is associated with reduced thyroid
autoantibody titers in deficient patients.
evidence:
- reference: PMID:38542128
reference_title: "Autoimmune Thyroiditis and Vitamin D."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "after the supplementation with cholecalciferol in patients with HT and vitamin D deficiency, thyroid autoantibody titers decreased significantly."
explanation: Cholecalciferol supplementation reduces thyroid autoantibody titers in vitamin D-deficient HT patients.
evidence:
- reference: PMID:38542128
reference_title: "Autoimmune Thyroiditis and Vitamin D."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "after the supplementation with cholecalciferol in patients with HT and vitamin D deficiency, thyroid autoantibody titers decreased significantly."
explanation: Supports vitamin D repletion as an adjunct that lowers autoantibody titers in deficient HT patients.
- name: Monitoring
description: Regular TSH monitoring to adjust replacement dose.
evidence:
- reference: PMID:35235282
reference_title: "Thyroid and Parathyroid Conditions: Hypothyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Thyroid hormone should be titrated based on goal TSH values, symptoms, and potential treatment adverse effects."
explanation: Ongoing TSH-based monitoring is required to titrate thyroid hormone replacement.
classifications:
harrisons_chapter:
- classification_value: ENDOCRINOLOGY_METABOLISM
evidence:
- reference: PMID:26235382
reference_title: "Immunogenetics of autoimmune thyroid diseases: A comprehensive review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Both environmental and genetic triggers factor into the etiology of autoimmune thyroid disease (AITD), including Graves' disease (GD) and Hashimoto's thyroiditis (HT)."
explanation: Hashimoto's thyroiditis is an autoimmune thyroid condition within endocrine system disorders.
- reference: PMID:26235382
reference_title: "Immunogenetics of autoimmune thyroid diseases: A comprehensive review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Both environmental and genetic triggers factor into the etiology of autoimmune thyroid disease (AITD), including Graves' disease (GD) and Hashimoto's thyroiditis (HT)."
explanation: Directly classifies HT as autoimmune thyroid disease.
- classification_value: IMMUNE_RHEUMATOLOGIC
evidence:
- reference: PMID:38731922
reference_title: "Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Hashimoto's thyroiditis (HT) is generally characterized by the presence of thyroid peroxidase and thyroglobulin antibodies, with a concomitant infiltration of lymphocytes in the thyroid."
explanation: Defines HT as an autoimmune disease with autoantibodies and lymphocytic infiltration.
discussions:
- discussion_id: gap_ht_tolerance_breaking_initiating_event
prompt: >-
What converts genetic susceptibility plus environmental exposure into the
first breach of tolerance to thyroid peroxidase and thyroglobulin, and can
that initiating event be observed before autoantibodies appear?
kind: KNOWLEDGE_GAP
status: OPEN
attaches_to:
- pathophysiology#Loss of Immune Tolerance to Thyroid Antigens
rationale: >-
Every mechanism curated downstream of this node is comparatively
well-evidenced, and the node itself is not. The entry wires four candidate
routes into it, hyperiodinated thyroglobulin, selenoprotein-limited
oxidative injury, weakened vitamin D-dependent immunoregulation, and
hepatitis C-associated immune activation, and none of them is shown to be
the initiating event rather than a contributing risk state. The 2026
openscientist hypothesis-search report reached the same conclusion after
checking viral triggers including SARS-CoV-2, iodine excess, gut dysbiosis,
epigenetic modification, and aberrant thyrocyte HLA class II expression,
calling the initiating event the single largest gap in the framework.
Without it, primary prevention and pre-seroconversion intervention have no
target. Resolution needs a longitudinal pre-disease cohort, for example
first-degree relatives followed from euthyroid antibody-negative baseline,
with serial immune phenotyping, autoantibody titres, microbiome and
epigenetic sampling, so that the ordering of events can be observed rather
than inferred from cross-sectional patient data.
- discussion_id: gap_ht_seronegative_effector_mechanism
prompt: >-
By what effector mechanism is the thyroid destroyed in patients who have
the ultrasound and functional picture of Hashimoto's thyroiditis but no
detectable anti-TPO or anti-thyroglobulin antibodies?
kind: KNOWLEDGE_GAP
status: OPEN
attaches_to:
- pathophysiology#Autoimmune Thyroid Destruction
- biochemical#Anti-TPO Antibodies
rationale: >-
Seronegative disease is a real and reproducible phenotype in both children
and adults, and it is consistently milder. It qualifies the entry's
autoantibody-centred serology without refuting it, because the antibodies
plausibly amplify severity rather than being required for destruction. What
is missing is any positive account of the effector mechanism in these
patients: whether they carry sub-threshold or intrathyroidal-only antibody,
whether the infiltrate is T-cell dominant without germinal-centre B-cell
help, or whether some of them are not autoimmune at all. The paediatric
series raises the last possibility directly, noting its seronegative group
is clinically superimposable on overweight children with the same
ultrasound changes and no antibodies, a reversible condition. Deep immune
profiling of seronegative thyroid tissue against seropositive and healthy
controls, with B-cell and T-cell receptor repertoire sequencing, would
separate these.
evidence:
- reference: PMID:35377135
reference_title: "Seronegative phenotype in a pediatric population with Hashimoto's thyroiditis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Prevalence of seronegative Hashimoto's thyroiditis in this cohort was 12.3% (19/154)."
explanation: >-
Establishes that a seronegative group exists and quantifies it in one
paediatric cohort of 154. The figure is cohort-specific and should not be
read as a general case fraction.
- reference: PMID:24743395
reference_title: "Serum negative autoimmune thyroiditis displays a milder clinical picture compared with classic Hashimoto's thyroiditis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "These results suggest an autoimmune etiology of SN-CAT, which, however, seems to have a milder clinical course when compared with CAT."
explanation: >-
Independent adult case-control series reaching the same conclusion, with
lower TSH, higher free T4, smaller thyroid volume and a lower prevalence
of overt hypothyroidism than seropositive disease.
- discussion_id: question_ht_igg4_thyroiditis_entity_status
prompt: >-
Is IgG4 thyroiditis a histopathological variant of Hashimoto's thyroiditis
or a thyroid manifestation of systemic IgG4-related disease that should be
modelled separately?
kind: OPEN_QUESTION
status: OPEN
attaches_to:
- disease#Hashimoto's Thyroiditis
rationale: >-
A surgical series separating 105 Hashimoto cases by IgG4 immunostaining
found the IgG4 group differs on age, sex ratio, rate of progression,
autoantibody level, and histology, with a fibrosis-dominant picture that
the T-cell and autoantibody destruction model curated in this entry does
not explain well. The same study rules out the simplest reconciliation,
that IgG4 thyroiditis is just the fibrous variant, since the two groups
only partially overlap. This entry currently has no has_subtypes block and
treats Hashimoto's thyroiditis as a single phenotype, so the question is
recorded here rather than resolved by inventing a subtype. Deciding it
needs comparative multi-omics of IgG4 thyroiditis against classical
Hashimoto and against systemic IgG4-related disease. Note the reported
proportion is a fraction of a thyroidectomy series, so it cannot be carried
over as a prevalence in the general Hashimoto population.
evidence:
- reference: PMID:22555173
reference_title: "Distinct histopathological features of Hashimoto's thyroiditis with respect to IgG4-related disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "IgG4 thyroiditis was associated with a patient population of a younger age, a lower female-to-male ratio, rapid progression, higher levels of thyroid autoantibodies, subclinical hypothyroidism, and diffuse sonographic echogenicity."
explanation: >-
Documents the clinical and serological separation between the IgG4 and
non-IgG4 groups within a single Hashimoto surgical cohort, which is what
makes the entity question worth posing.
- discussion_id: emerging_ht_sex_biased_plasma_b_cell_homing
prompt: >-
Does constitutive CXCL13-CXCR5-driven plasma B cell homing to the female
thyroid explain the marked female predominance of Hashimoto's thyroiditis?
kind: EMERGING_HYPOTHESIS
status: OPEN
attaches_to:
- pathophysiology#Lymphocytic Infiltration
rationale: >-
The entry records a female-predominant autoimmune disease without offering
any mechanism for the sex bias. A 2024 study of thyroids deliberately
screened to exclude clinical autoimmune disease found sex differences in
plasma-B-cell gene programmes and localised the recruitment to the
CXCL13-CXCR5 axis by single-cell and spatial transcriptomics. If a
B-cell-permissive niche is already present in the healthy female thyroid,
then the sex bias would sit upstream of everything curated here, in the
baseline tissue state rather than in the disease process. Recorded as an
emerging hypothesis rather than wired as a causal edge, because the study
is in non-diseased tissue and the link to disease incidence is the authors'
own inference, framed as a possible contribution.
evidence:
- reference: PMID:39487734
reference_title: "Sex-Based Differences in Thyroid Plasma B Cell Infiltration: Implications for Autoimmune Disease Susceptibility."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Single-cell RNA-seq and spatial transcriptomic analyses further revealed that the CXCL13-CXCR5 signaling axis plays a pivotal role in recruiting and organizing plasma B cells within the thyroid tissue."
explanation: >-
Identifies the chemokine axis organising plasma B cells in thyroid
tissue, the proposed substrate for a sex-biased predisposition.
- discussion_id: gap_ht_no_disease_modifying_therapy
prompt: >-
Can any intervention halt or reverse the autoimmune process in Hashimoto's
thyroiditis, as opposed to replacing the hormone the destroyed gland no
longer makes or lowering an antibody titre?
kind: KNOWLEDGE_GAP
status: OPEN
attaches_to:
- treatments#
rationale: >-
Every treatment curated in this entry is either replacement, which bypasses
the lesion, or a biomarker-level modulator. Selenium lowers thyroid
peroxidase antibody but a 412-patient double-blind trial already recorded
here found no quality-of-life benefit over placebo, and a GRADE overview
rates the antibody effect itself as low certainty, so the biomarker-outcome
dissociation is documented rather than hypothetical. The one report of
genuine disease modification is a single patient whose antibodies
normalised and who came off levothyroxine while taking a JAK inhibitor for
an unrelated indication. That is a lead, not a therapy. Resolution needs a
randomised trial in early seropositive disease with preservation of thyroid
function as the primary endpoint, not antibody titre.
evidence:
- reference: PMID:42039112
reference_title: "Resolution of Hashimoto thyroiditis with Janus kinase inhibitor therapy in a patient with alopecia universalis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We report a case of a 44-year-old woman with both alopecia universalis and HT who experienced normalization of TPO antibody levels, no longer requiring thyroid hormone treatment following JAK inhibitor therapy for alopecia universalis-suggesting possible reversal of HT."
explanation: >-
The strongest available signal that the destructive process is
pharmacologically reversible, and simultaneously the measure of how thin
that evidence is. The source claims only possible reversal in one
patient.
- reference: PMID:37513612
reference_title: "The Effects of Selenium Supplementation in the Treatment of Autoimmune Thyroiditis: An Overview of Systematic Reviews."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Although selenium supplementation might reduce TPO-Ab levels at 3 and 6 months and Tg-Ab levels at 3 and 6 months in the non-LT4-treated population, this was based on a low certainty of evidence."
explanation: >-
An overview of six systematic reviews covering 75 randomised trials rates
the certainty of even the antibody-lowering effect as low, which is why
selenium cannot be counted as disease-modifying therapy.
- discussion_id: gap_ht_exosome_release_inhibition_translation
prompt: >-
Does blocking exosome release, or supplying engineered mesenchymal stem
cell-derived exosomes, restore immune homeostasis in human Hashimoto's
thyroiditis, or is the effect confined to the cell and animal systems it has
been shown in?
kind: KNOWLEDGE_GAP
status: OPEN
attaches_to:
- pathophysiology#Loss of Immune Tolerance to Thyroid Antigens
- pathophysiology#Th17/Treg Imbalance
- pathophysiology#NF-κB-IL-6 Signaling Pathway Activation
- treatments#
rationale: >-
The entry now curates three exosome-dependent mechanisms upstream of
thyrocyte destruction, and none of the four treatments it lists acts on any
of them: levothyroxine replaces the missing hormone, and selenium and
vitamin D are supplements with weak or absent disease-modifying effect. That
makes exosome release a stated therapeutic direction for a disease whose
curated therapy is entirely downstream of the lesion, which is why the gap
is worth recording rather than leaving implicit. What is missing is any
human evidence. GW4869 is a neutral sphingomyelinase inhibitor used as a
laboratory tool for blocking exosome secretion; it has no approved clinical
indication, no trial in thyroid autoimmunity, and no NCIT
clinical-intervention identity in this disease, so it is deliberately not
curated as a treatment here. Engineered MSC-derived exosomes are at the same
stage. Resolving this needs, at minimum, a demonstration that exosome
blockade changes thyroid autoimmunity in an immunocompetent in vivo model of
HT rather than in cell co-culture, followed by a safety-and-target-engagement
study in humans — exosome secretion is constitutive and not thyroid-specific,
so the plausible off-target cost of inhibiting it systemically is itself
unquantified.
evidence:
- reference: PMID:42631765
reference_title: "Exosome in Hashimoto's thyroiditis: from pathogenesis to diagnostic and therapeutic potential."
supports: SUPPORT
quote_role: REVIEW_SYNTHESIS
evidence_source: OTHER
snippet: "Therapeutically, inhibition of exosome release (e.g., GW4869) and the use of engineered mesenchymal stem cell-derived exosomes demonstrate promising potential for restoring immune homeostasis."
explanation: >-
The sentence that states the therapeutic direction, and the reason it is
recorded as a gap rather than a treatment. It is the review's forward-looking
synthesis of preclinical work, naming no study design, model, species or
outcome measure, so it is graded OTHER: there is no single study type behind
it to classify.
notes: >-
Also the home of a deferred design question raised in review of PR #12110:
whether exosome-mediated intercellular signalling should become a
pathophysiology node in its own right, with downstream edges into the three
nodes listed in attaches_to. It would make the mechanism queryable and would
give this therapeutic direction a target_mechanisms anchor, which it
currently lacks. Deferred rather than done here because the cited review is a
single secondary source: it establishes that exosomes carry these three
cargoes, but a node asserting exosome signalling as a discrete causal step
should rest on the primary studies, and building it would also mean deciding
whether one node covers all three cargoes or each cargo is its own. Recorded
so the option is not lost.
datasets:
- accession: gtex:GTEx_v8_Thyroid
title: GTEx v8 Thyroid tissue RNA-seq in Hashimoto case-control analysis
description: >
Bulk RNA-seq analysis of thyroid tissue from GTEx v8 used in a case-control
comparison of histopathologically confirmed Hashimoto's thyroiditis and
matched controls.
organism:
preferred_term: Homo sapiens
term:
id: NCBITaxon:9606
label: Homo sapiens
data_type: BULK_RNA_SEQ
sample_types:
- preferred_term: thyroid gland
term:
id: UBERON:0002046
label: thyroid gland
tissue_term:
preferred_term: thyroid gland
term:
id: UBERON:0002046
label: thyroid gland
sample_count: 104
conditions:
- Histopathologically confirmed Hashimoto's thyroiditis tissue
- Matched non-Hashimoto thyroid tissue controls
publication: PMID:33085325
evidence:
- reference: DOI:10.48188/so.6.9
reference_title: "Transcriptome analysis of thyroid tissue in patients with Hashimoto’s disease using next-generation sequencing: case–control study"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "As part of a case–control design, we analyzed thyroid tissue RNA sequencing libraries from the Genotype-Tissue Expression Project (v8 release)."
explanation: The dataset entry captures the GTEx v8 thyroid RNA-seq source used to compare Hashimoto and control thyroid tissue transcriptomes.
references:
- reference: DOI:10.1038/s41467-024-50192-5
title: Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution
findings: []
- reference: DOI:10.3389/fendo.2025.1584675
title: Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms
findings: []
- reference: DOI:10.48188/so.6.9
title: 'Transcriptome analysis of thyroid tissue in patients with Hashimoto’s disease using next-generation sequencing: case–control study'
findings: []
References & Deep Research
References
3Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution
No top-level findings curated for this source.
Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms
No top-level findings curated for this source.
Transcriptome analysis of thyroid tissue in patients with Hashimoto’s disease using next-generation sequencing: case–control study
No top-level findings curated for this source.
Deep Research
2Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.
Evaluations and curation notes (1)
Augment Hashimoto thyroiditis: build causal pathograph and add Edison deep-research findings · 2026-07-16T22:42:32Z · View source
Built out the previously-empty causal pathograph by adding downstream, sequelae, biomarker readout, and treatment target_mechanism edges that connect all mechanism, phenotype, biochemical, genetic, and treatment nodes into one connected graph of 27 nodes with no orphans. Added two upstream mechanism nodes: Loss of Immune Tolerance to Thyroid Antigens carrying CTLA4/PTPN22/LAG3, and Thyrocyte Antigen Presentation via CD74/MIF. Conformed the Thyroid Hormone Deficiency node to the hypothyroidism_thyroid_hormone_deficiency module. Edison falcon deep research via EDISON_API_KEY (30 citations, 2 artifacts) contributed the LAG3 start-codon risk variant PMID:38982041, vitamin D deficiency risk plus supplementation PMID:38542128, and selenium quality-of-life RCT nuance PMID:38215286. Attached the open-access CC-BY Nature Communications figure PMID:39003267 to the antigen-presentation node. Validated with just validate; schema, terms, and references all pass; pathograph builds cleanly.
Disorder
▸
Disorder
- Name: Hashimoto's Thyroiditis
- Category: Complex
- Existing deep-research providers: falcon
- Existing evidence reference count in YAML: 13
Key Pathophysiology Nodes
- Autoimmune Thyroid Destruction
- Lymphocytic Infiltration
- Thyroid Hormone Deficiency
- Deep research literature mapping
Citation Inventory (for evidence mapping)
- DOI:10.1038/s41467-024-50192-5
- DOI:10.3389/fendo.2025.1584675
- DOI:10.48188/so.6.9
Falcon
▸
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Disease Characteristics Research Template
Target Disease
- Disease Name: Hashimoto's Thyroiditis
- MONDO ID: (if available)
- Category: Complex
Research Objectives
Please provide a comprehensive research report on Hashimoto's Thyroiditis covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.
For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.
1. Disease Information
Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed
- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?
2. Etiology
- Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- Risk Factors:
Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
- Genetic risk factors (causal variants, susceptibility loci, modifier genes)
- Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- Protective Factors:
Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
- Genetic protective factors (protective variants, modifier alleles)
- Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?
Search first: CTD, PubMed, PheGenI, GxE databases
3. Phenotypes
Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC
For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype
4. Genetic/Molecular Information
- Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- Pathogenic Variants:
- Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
- Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
- Variant type/class (missense, frameshift, nonsense, splice-site, structural)
- Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
- Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
- Functional consequences (loss of function, gain of function, dominant negative)
- Modifier Genes: Genes that modify disease severity or expression
- Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)
Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser
5. Environmental Information
- Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)
Search first: CDC databases, WHO, PubMed, NHANES
- Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON
6. Mechanism / Pathophysiology
- Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
- Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
- Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
- Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
Search first: PubMed, Gene Ontology, Reactome
- Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
- Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- Molecular Profiling (if available):
- Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
- Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
- Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
- Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
- Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- Advanced Technologies (if applicable):
- Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
- Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
- Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
- Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS
For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types
7. Anatomical Structures Affected
- Organ Level:
- Primary organs directly affected
- Secondary organ involvement (complications, secondary effects)
- Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- Tissue and Cell Level:
- Specific tissue types affected (epithelial, connective, muscle, nervous)
- Specific cell populations targeted (with Cell Ontology terms)
Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- Subcellular Level:
- Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- Localization:
- Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
- Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases
8. Temporal Development
- Onset:
- Typical age of onset (congenital, pediatric, adult, geriatric)
- Onset pattern (acute, subacute, chronic, insidious)
Search first: OMIM, Orphanet, HPO, PubMed
- Progression:
- Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
- Progression rate (rapid, slow, variable)
- Disease course pattern (episodic, relapsing-remitting, progressive, stable)
- Disease duration (self-limited, chronic lifelong)
Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- Patterns:
- Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
- Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines
9. Inheritance and Population
- Epidemiology:
- Prevalence (cases per 100,000 at given time)
- Incidence (new cases per 100,000 per year)
Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- For Genetic Etiology:
- Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
- Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
- Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
- Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
- Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
- Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
- Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
- Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
- Population Demographics:
- Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
- Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
- Geographic distribution of specific variants
- Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
- Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet
10. Diagnostics
- Clinical Tests:
- Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
- Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
- Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
- Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
- Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
- Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
- Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
- Genetic Testing:
Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
- Overview of recommended genetic testing approach
- Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
- Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
- Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
- Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
- Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
- Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
- FISH > Search first: ClinVar, cytogenetics databases, PubMed
- Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
- Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
- Omics-Based Diagnostics (if applicable):
- RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
- Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
- Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
- Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
- Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
- Clinical Criteria:
- Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
- Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
- Screening:
- Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR
11. Outcome/Prognosis
- Survival and Mortality:
- Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
- Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
- Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
- Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
- Morbidity and Function:
- Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
- Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
- Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
- Disease Course:
- Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
- Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
- Prediction:
- Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
- Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases
12. Treatment
- Pharmacotherapy:
- Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
- Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- Advanced Therapeutics:
- Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
- Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
- RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
- Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
- Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- Surgical and Interventional:
- Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
- Supportive and Rehabilitative:
- Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
- Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
- Experimental:
- Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- Treatment Outcomes:
- Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
- Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- Treatment Strategy:
- Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
- Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
- Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases
For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.
13. Prevention
- Prevention Levels:
- Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
- Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
- Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
- Immunization: Vaccine strategies (if applicable)
Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
- Screening and Early Detection:
- Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
- Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
- Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
- Behavioral Interventions: Lifestyle modifications to reduce risk
Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
- Counseling: Genetic counseling (risk assessment, family planning guidance)
Search first: NSGC resources, ACMG guidelines, GeneReviews
- Public Health:
- Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
- Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
- Prophylaxis: Preventive medications or procedures
Search first: Clinical guidelines, FDA approvals, PubMed
14. Other Species / Natural Disease
- Taxonomy: Species affected (with NCBI Taxon identifiers)
Search first: NCBI Taxonomy
- Breed: Specific breeds affected (with VBO identifiers if applicable)
Search first: VBO (Vertebrate Breed Ontology)
- Gene: Orthologous genes in other species (with NCBI Gene IDs)
Search first: NCBI Gene
- Natural Disease:
- Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
- Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
- Comparative Biology:
- Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
- Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
- Transmission (if applicable):
- Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
- Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed
15. Model Organisms
- Model Types:
- Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
- Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
- Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
- Genetic Models:
- Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
- Model Characteristics:
- Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
- Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
- Applications:
- Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
- Resources:
- Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC
Citation Requirements
- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational
Output Format
Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease
This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details
Hashimoto’s Thyroiditis (HT): Comprehensive Disease Characteristics Report (2023–2024 emphasis)
Target disease
- Disease name: Hashimoto’s thyroiditis (HT)
- Category: Complex / polygenic autoimmune disease
- MONDO ID: Not confirmed from the retrieved evidence in this run (should be programmatically looked up in MONDO; not inferred here).
Executive overview
Hashimoto’s thyroiditis is a chronic organ-specific autoimmune disease characterized by lymphocytic inflammation of the thyroid gland, circulating autoantibodies against thyroid antigens (notably thyroid peroxidase and thyroglobulin), characteristic ultrasound patterns, and a progressive course that commonly culminates in hypothyroidism requiring lifelong thyroid hormone replacement therapy (levothyroxine). (huwiler2024seleniumsupplementationin pages 1-2, kolanu2024fromantibodiesto pages 2-3)
A large 2024 GWAS meta-analysis in autoimmune thyroid disease (AITD; encompassing HT and related phenotypes) underscores extensive polygenicity and highlights genes involved in T-cell regulation; it identifies a rare start-codon/5′UTR LAG3 variant with a large effect size and functional evidence of reduced inhibitory checkpoint expression. (saevarsdottir2024startcodonvariant pages 7-8)
A 2024 Nature Communications spatial transcriptomics study provides high-resolution mechanistic insight into HT tissue architecture, emphasizing aberrant antigen presentation by thyroid follicular cells (CD74/MIF axis), immune infiltration (T cells, B cells, macrophages), inflammatory fibroblast programs, and vascular remodeling facilitating immune trafficking. (martinezhernandez2024unravelingthemolecular pages 1-2, martinezhernandez2024unravelingthemolecular pages 9-12, martinezhernandez2024unravelingthemolecular pages 13-14)
1. Disease information
1.1 What is the disease?
HT (also referred to as chronic autoimmune/lymphocytic thyroiditis) is described as a chronic autoimmune condition affecting the thyroid, driven by dysregulated T- and B-cell immune responses with thyroid infiltration by autoreactive lymphocytes and antibody production. (kolanu2024fromantibodiesto pages 2-3, huwiler2024seleniumsupplementationin pages 1-2)
1.2 Key identifiers and terminology
- Synonyms: chronic autoimmune thyroiditis; chronic lymphocytic thyroiditis; autoimmune thyroiditis; Hashimoto disease. (huwiler2024seleniumsupplementationin pages 1-2, kolanu2024fromantibodiesto pages 1-2)
- ICD-10 (suggested): E06.3 (autoimmune thyroiditis). (Not directly evidenced in retrieved texts; included as a standard clinical code suggestion—verify against ICD tables in implementation.)
- MeSH (suggested): Hashimoto Disease. (Not directly evidenced in retrieved texts; verify via MeSH lookup in implementation.)
1.3 Evidence source type
The information in this report is derived from aggregated evidence sources (systematic reviews/meta-analyses, narrative reviews, human genetics studies, and spatial transcriptomics of human thyroid tissue), plus clinical trial registry entries (ClinicalTrials.gov). (huwiler2024seleniumsupplementationin pages 1-2, saevarsdottir2024startcodonvariant pages 7-8, martinezhernandez2024unravelingthemolecular pages 1-2, NCT05871957 chunk 1)
2. Etiology
2.1 Disease causal factors (current understanding)
HT etiology is multifactorial, involving genetic susceptibility and environmental triggers leading to breakdown of immune tolerance, lymphocytic infiltration, and thyroid tissue destruction. Reviews highlight genetic factors (e.g., HLA-DR, CTLA4) and environmental triggers such as excess dietary iodine and toxicant exposures. (kolanu2024fromantibodiesto pages 2-3)
2.2 Risk factors
- Sex: Multiple sources emphasize a strong female predominance (reported as women being 4–10× more susceptible than men). (huwiler2024seleniumsupplementationin pages 1-2)
- Micronutrient status: A 2024 review emphasizes that vitamin D levels are significantly lower in HT patients than controls and discusses supplementation as potentially antibody-lowering in deficient individuals. (duratrave2024autoimmunethyroiditisand pages 1-2)
2.3 Protective factors
Within the retrieved evidence, clear protective genetic variants or protective environmental exposures specific to HT were not explicitly identified; the main genetic evidence emphasizes risk loci and risk-increasing variants in immune regulatory genes. (saevarsdottir2024startcodonvariant pages 7-8)
2.4 Gene–environment interactions
The retrieved evidence supports the general framework of interaction among genetic influences, environmental triggers, and epigenetic effects in HT pathogenesis, but does not provide a specific, quantified gene–environment interaction effect size within the accessed texts. (duratrave2024autoimmunethyroiditisand pages 1-2)
3. Phenotypes
3.1 Core phenotypes and HPO suggestions
A diagnostic review describes common hypothyroid-associated symptoms including fatigue, weight gain, cold sensitivity, dry skin, and constipation. (kolanu2024fromantibodiesto pages 2-3)
Suggested HPO terms (examples) for knowledge base population: - Fatigue; Weight gain; Cold intolerance; Dry skin; Constipation; Hypothyroidism. (kolanu2024fromantibodiesto pages 2-3)
3.2 Laboratory abnormalities
Key laboratory features used in diagnosis include elevated TSH with decreased FT4/FT3 in overt hypothyroidism and detection of anti-TPO and anti-thyroglobulin antibodies as autoimmune markers. (kolanu2024fromantibodiesto pages 2-3)
3.3 Imaging and pathology phenotypes
- Ultrasound: heterogeneous echotexture and diffuse hypoechogenicity. (kolanu2024fromantibodiesto pages 2-3)
- Histopathology: lymphocytic infiltrates and germinal centers can be observed on fine-needle aspiration/biopsy; spatial transcriptomics corroborates immune-rich infiltrates with T cells, B cells, and inflammatory macrophages. (kolanu2024fromantibodiesto pages 2-3, martinezhernandez2024unravelingthemolecular pages 1-2)
3.4 Quality of life impact
HT can have persistent quality-of-life (QoL) burden even when biochemical targets are met; a 2024 review highlights that some patients report suboptimal HRQoL despite normalized TSH/T4. (huang2024traditionalchinesemedicine pages 4-5)
4. Genetic/molecular information
4.1 Genetic architecture (polygenic susceptibility)
A 2024 Nature Communications GWAS meta-analysis in AITD reports 110,945 cases and 1,084,290 controls, identifying 290 sequence variants at 225 loci (including 115 previously unreported), and emphasizes genes involved in T-cell regulation. (saevarsdottir2024startcodonvariant pages 7-8)
Abstract quote (genetics scale): “In a GWAS meta-analysis of 110,945 cases and 1,084,290 controls, 290 sequence variants at 225 loci are associated with AITD.” (saevarsdottir2024startcodonvariant pages 7-8)
4.2 Notable high-effect variant (LAG3)
The same study highlights a rare LAG3 variant (rs781745126-T) that creates a novel upstream start codon and is associated with increased AITD risk and functional reduction of LAG-3 expression. - Effect size: OR 3.42 with P = 2.2×10⁻¹⁶ (as reported in the abstract snippet). (saevarsdottir2024startcodonvariant pages 7-8) - Functional evidence: reduced LAG3 mRNA and surface expression on activated lymphocyte subsets and ~half plasma LAG-3 in heterozygotes; all three homozygous carriers had AITD. (saevarsdottir2024startcodonvariant pages 7-8)
4.3 Candidate genes outside MHC and immune regulation
The genetics evidence points to immune checkpoint and T-cell receptor signaling genes (e.g., LAG3 and ZAP70) as biologically coherent candidates linking inherited variation to immune dysregulation in AITD/HT-relevant phenotypes. (saevarsdottir2024startcodonvariant pages 7-8)
4.4 Epigenetic information
The accessed evidence notes epigenetic effects as part of the causal framework but does not provide specific methylation loci/histone marks within retrieved texts in this run. (duratrave2024autoimmunethyroiditisand pages 1-2)
5. Environmental information
5.1 Environmental and lifestyle contributors
A diagnostic-focused review lists environmental triggers including excess dietary iodine and toxicants as influences on disease development in susceptible individuals. (kolanu2024fromantibodiesto pages 2-3)
5.2 Infectious agents
No specific pathogen with causal attribution was supported by the retrieved evidence snippets in this run.
6. Mechanism / pathophysiology
6.1 Causal chain (immune dysregulation → tissue injury → hypothyroidism)
Across sources, a coherent mechanism emerges: 1) Genetic susceptibility and environmental triggers contribute to loss of tolerance and immune activation. (kolanu2024fromantibodiesto pages 2-3, duratrave2024autoimmunethyroiditisand pages 1-2, saevarsdottir2024startcodonvariant pages 7-8) 2) Thyroid-resident and infiltrating immune cells participate in antigen presentation and inflammatory amplification, including aberrant antigen presentation signatures in thyroid follicular cells. (martinezhernandez2024unravelingthemolecular pages 1-2, martinezhernandez2024unravelingthemolecular pages 9-12) 3) Chronic immune-mediated follicular injury and tissue remodeling progressively impair hormone synthesis, leading to hypothyroidism requiring replacement therapy. (huwiler2024seleniumsupplementationin pages 1-2, huang2024traditionalchinesemedicine pages 4-5)
6.2 Spatial transcriptomics (2024) and cell-type resolved mechanisms (high-authority primary research)
A 2024 Nature Communications study used spatial transcriptomics to resolve thyroid tissue architecture in AITD, including HT.
Key mechanistic findings relevant to HT: - Damaged thyroid follicular cells (TFCs) and antigen presentation: TFCs show upregulated CD74 and MIF, consistent with aberrant antigen presentation and immune communication. (martinezhernandez2024unravelingthemolecular pages 1-2, martinezhernandez2024unravelingthemolecular pages 12-13) - Immune infiltration: HT tissue demonstrates rich lymphocytic infiltrates (T cells, B cells) and inflammatory macrophages; borderline infiltrate zones show T-cell gene expression (e.g., TRAC/TRBC1/CD3D) and B-cell markers (MS4A1/CR2). (martinezhernandez2024unravelingthemolecular pages 1-2, martinezhernandez2024unravelingthemolecular pages 9-12) - Fibroblast programs and remodeling: inflammatory-associated fibroblasts (e.g., CXCL12+ and IGFBP6+ programs) are enriched in HT and linked to chemotaxis and extracellular matrix remodeling/destruction. (martinezhernandez2024unravelingthemolecular pages 13-14) - Vascular remodeling: endothelial features that facilitate immune trafficking are described, including specialized vessels (ACKR1+ high endothelial venules in infiltrated regions). (martinezhernandez2024unravelingthemolecular pages 9-12) - Cytokine amplification: IFN-γ and TNF-α can upregulate CD74 in TFCs and infiltrating immune cells, potentially amplifying ligand–receptor interactions and antigen-presentation pathways. (martinezhernandez2024unravelingthemolecular pages 9-12, martinezhernandez2024unravelingthemolecular pages 12-13)
Visual evidence (mechanistic schematic)
Figure 8 from Martínez-Hernández et al. summarizes an HT model with damaged CD74-high TFCs, a CD74/MIF loop, inflammatory fibroblast subtypes, and vascular/immune infiltration mechanisms. (martinezhernandez2024unravelingthemolecular media c4e4de12, martinezhernandez2024unravelingthemolecular media b04d5261)
6.3 Suggested ontology mappings for mechanisms
Examples aligned to evidence: - GO Biological Process (suggested): antigen processing and presentation via MHC class II; T cell activation; lymphocyte chemotaxis; extracellular matrix organization; regulation of vascular permeability. (martinezhernandez2024unravelingthemolecular pages 9-12, martinezhernandez2024unravelingthemolecular pages 13-14) - Cell Ontology (CL; suggested): thyroid follicular cell; T cell; B cell; macrophage; dendritic cell; fibroblast; endothelial cell. (martinezhernandez2024unravelingthemolecular pages 1-2, martinezhernandez2024unravelingthemolecular pages 9-12, martinezhernandez2024unravelingthemolecular pages 13-14)
7. Anatomical structures affected
7.1 Primary organ
- Thyroid gland (primary site of inflammation, immune infiltration, tissue remodeling, and follicular injury). (huwiler2024seleniumsupplementationin pages 1-2, martinezhernandez2024unravelingthemolecular pages 1-2)
7.2 Tissue and cell level
Key implicated compartments/cell types in HT thyroid tissue include thyroid follicular epithelial cells, stromal fibroblast subtypes, endothelial cells, and infiltrating lymphocytes and macrophages. (martinezhernandez2024unravelingthemolecular pages 1-2, martinezhernandez2024unravelingthemolecular pages 13-14)
8. Temporal development
HT is typically chronic and insidious with variable progression, often culminating in hypothyroidism over time. (kolanu2024fromantibodiesto pages 1-2, huwiler2024seleniumsupplementationin pages 1-2)
9. Inheritance and population
9.1 Inheritance pattern
Evidence supports a polygenic/multifactorial inheritance architecture rather than single-gene Mendelian inheritance, based on large-scale GWAS results with many loci. (saevarsdottir2024startcodonvariant pages 7-8)
9.2 Epidemiology (statistics)
- Global burden: HT has been described as affecting approximately 160 million people globally and is characterized as the most common cause of hypothyroidism in iodine-sufficient regions. (huwiler2024seleniumsupplementationin pages 1-2)
- Sex ratio: women 4–10× more susceptible than men. (huwiler2024seleniumsupplementationin pages 1-2)
- Incidence: approximately 0.3–1.5 per 1,000 persons reported in a 2024 review. (duratrave2024autoimmunethyroiditisand pages 1-2)
- Prevalence: a 2024 diagnostic review reports global prevalence of 7.5%, rising to 11.4% in low- and middle-income countries (note: these are review-level estimates; confirm with population-based epidemiology during KB curation). (kolanu2024fromantibodiesto pages 1-2)
10. Diagnostics
10.1 Standard diagnostic elements
Evidence supports a multi-component approach: - Laboratory: elevated TSH and low FT4/FT3 in overt hypothyroidism; anti-TPO and anti-thyroglobulin antibodies as key autoimmune markers. (kolanu2024fromantibodiesto pages 2-3) - Seronegative HT: antibody-negative disease can occur (~5–10% reported), complicating diagnosis. (kolanu2024fromantibodiesto pages 1-2) - Ultrasound: heterogeneous echotexture and diffuse hypoechogenicity. (kolanu2024fromantibodiesto pages 2-3) - Histology/cytology: lymphocytic infiltrates and germinal centers may be observed; spatial transcriptomics confirms compartmentalized immune infiltration. (kolanu2024fromantibodiesto pages 2-3, martinezhernandez2024unravelingthemolecular pages 1-2)
10.2 Emerging diagnostics and technology
A 2024 diagnostic review describes emerging modalities (microRNA profiling, genetic markers, artificial intelligence approaches) as potential tools to improve diagnostic precision, particularly in complex or seronegative cases. (kolanu2024fromantibodiesto pages 5-6)
11. Outcome / prognosis
The retrieved evidence emphasizes chronicity and progression to hypothyroidism requiring lifelong therapy, but does not provide direct survival/mortality metrics or long-term disability statistics within accessed excerpts. (huwiler2024seleniumsupplementationin pages 1-2)
QoL: Persistent symptoms can occur despite biochemical normalization, motivating research into adjunctive strategies and patient-reported outcomes. (huang2024traditionalchinesemedicine pages 4-5)
12. Treatment
12.1 Standard-of-care pharmacotherapy
Levothyroxine (LT4) replacement is standard once hypothyroidism develops, typically lifelong, aiming to normalize serum TSH. (huwiler2024seleniumsupplementationin pages 1-2, huang2024traditionalchinesemedicine pages 4-5)
Clinical/therapeutic gap: LT4 corrects hormone deficiency but does not directly address upstream autoimmunity, inflammation, or oxidative stress; some patients report ongoing symptoms/HRQoL impairment despite normalized thyroid labs. (huang2024traditionalchinesemedicine pages 4-5)
12.2 Selenium supplementation (evidence synthesis + RCT)
2024 systematic review/meta-analysis (Thyroid; DOI:10.1089/thy.2023.0556; searched through Jan 2023; published Mar 2024): - TSH reduction in patients not on thyroid hormone replacement: SMD −0.21 (95% CI −0.43 to −0.02; 7 cohorts; n=869). (huwiler2024seleniumsupplementationin pages 1-2) - TPOAb reduction: SMD −0.96 (95% CI −1.36 to −0.56; 29 cohorts; n=2,358). (huwiler2024seleniumsupplementationin pages 1-2) - Adverse effects: OR 0.89 (95% CI 0.46 to 1.75; 16 cohorts; n=1,339), suggesting no clear increase in adverse events vs controls. (huwiler2024seleniumsupplementationin pages 1-2)
Abstract quote (meta-analysis results): “Our meta-analysis found that selenium supplementation decreased TSH in patients without THRT (SMD −0.21 …) [and] TPOAb (SMD −0.96 …) … Adverse effects were comparable between the intervention and control groups (OR 0.89 …).” (huwiler2024seleniumsupplementationin pages 1-2)
2024 multicenter double-blind RCT (European Thyroid Journal; Jan 2024; DOI:10.1530/etj-23-0175): - Population: 412 adults with autoimmune thyroiditis on LT4; 200 μg selenium/day vs placebo; 332 (81%) completed intervention. (larsen2024seleniumsupplementationand pages 1-2) - QoL: no between-group difference (ThyPRO-39 composite score 28.8 vs 28.0; P=0.602). (larsen2024seleniumsupplementationand pages 1-2) - Antibodies: lower TPOAb at 12 months in selenium group (1995 vs 2344 kIU/L; P=0.016). (larsen2024seleniumsupplementationand pages 1-2)
Interpretation (expert synthesis from evidence): Selenium supplementation appears to consistently lower antibody titers (biochemical effect), but high-quality RCT evidence indicates this does not necessarily translate to QoL benefit in LT4-treated hypothyroid autoimmune thyroiditis over 12 months, highlighting a biomarker–outcome dissociation relevant to clinical implementation. (larsen2024seleniumsupplementationand pages 1-2, huwiler2024seleniumsupplementationin pages 1-2)
12.3 Vitamin D (risk association and supplementation rationale)
A 2024 narrative review emphasizes vitamin D’s immunomodulatory role and reports that vitamin D levels are “significantly lower” in HT patients and that antibody titers “decreased significantly” after cholecalciferol supplementation in deficient patients, while calling for more randomized, placebo-controlled trials. (duratrave2024autoimmunethyroiditisand pages 1-2)
Abstract quote: “There is extensive literature confirming that vitamin D levels are significantly lower in HT patients compared to healthy people. On the other hand, after the supplementation with cholecalciferol in patients with HT and vitamin D deficiency, thyroid autoantibody titers decreased significantly.” (duratrave2024autoimmunethyroiditisand pages 1-2)
12.4 Experimental/registry-listed interventional strategies (ClinicalTrials.gov)
- Vitamin D as adjuvant (observational): NCT05871957; 30 female participants; vitamin D 2000 IU/day for 1 month; primary outcome TPOAb; secondary outcomes TgAb, FT3/FT4/TSH; registry indicates not-yet-recruiting at time of record. (NCT05871957 chunk 1)
- Hydroxychloroquine (immunomodulation): NCT01760421; single-group interventional; 40 euthyroid adults; hydroxychloroquine 200 mg twice daily for 6 months; primary outcomes anti-TPO and anti-thyroglobulin antibodies; secondary outcomes include elastography and cytokines (IL-1/IL-6/TNF-α). (NCT01760421 chunk 1)
- Dietary intervention: NCT05949671; compares gluten-free and Mediterranean dietary approaches over 12 weeks with dietitian support; enrollment reported as 40 in registry retrieval; primary outcome relates to autoimmune system effects. (NCT05949671 chunk 2)
- Photobiomodulation therapy: NCT06735040; interventional study in HT patients on LT4; enrollment reported as 60; outcomes include depression/anxiety/fatigue measures over ~3 months. (NCT06735040 chunk 2)
13. Prevention
The retrieved evidence does not define an established primary prevention strategy for HT. Secondary prevention in practice centers on early detection of thyroid dysfunction and autoimmunity (TSH/FT4 and thyroid antibody testing) and timely management of hypothyroidism to prevent complications; this is implied by standard diagnostic/treatment paradigms rather than explicitly quantified in accessed excerpts. (kolanu2024fromantibodiesto pages 2-3, huwiler2024seleniumsupplementationin pages 1-2)
14. Other species / natural disease
No cross-species naturally occurring HT evidence was available in the retrieved excerpts for this run.
15. Model organisms
The retrieved excerpts did not provide specific model organism systems for HT, though mechanistic frameworks (immune tolerance breakdown, oxidative stress) are compatible with commonly used experimental autoimmune thyroiditis models (not evidenced here; do not infer without retrieval).
High-yield structured summary table (for knowledge base ingestion)
| Category | Item | Details (include quantitative stats where available) | Ontology/Identifier suggestions | Key supporting sources |
|---|---|---|---|---|
| Disease overview / identifiers / synonyms | Definition | Autoimmune thyroid disease characterized by chronic lymphocytic inflammation of the thyroid, thyroid autoantibodies, progressive follicular damage, and frequent progression to hypothyroidism; standard treatment after hypothyroidism develops is lifelong levothyroxine replacement (huwiler2024seleniumsupplementationin pages 1-2, kolanu2024fromantibodiesto pages 2-3, huang2024traditionalchinesemedicine pages 4-5) | MeSH: Hashimoto Disease; ICD-10: E06.3 Autoimmune thyroiditis; ICD-11: autoimmune thyroiditis; MONDO: Hashimoto thyroiditis if mapped in KB; UBERON: thyroid gland | Huwiler 2024, DOI: 10.1089/thy.2023.0556; Kolanu 2024, DOI: 10.7759/cureus.54393; Huang 2024, DOI: 10.3390/antiox13070868 |
| Disease overview / identifiers / synonyms | Synonyms | Common synonyms: chronic autoimmune thyroiditis, chronic lymphocytic thyroiditis, autoimmune thyroiditis, Hashimoto disease (huwiler2024seleniumsupplementationin pages 1-2, kolanu2024fromantibodiesto pages 1-2) | MeSH synonym set; SNOMED/ICD cross-map as available | Huwiler 2024, DOI: 10.1089/thy.2023.0556; Kolanu 2024, DOI: 10.7759/cureus.54393 |
| Epidemiology | Prevalence / incidence / sex | Review sources report global prevalence about 7.5%, rising to 11.4% in LMICs; incidence about 0.3–1.5 per 1,000 persons; women affected 4–10× more often than men (kolanu2024fromantibodiesto pages 1-2, duratrave2024autoimmunethyroiditisand pages 1-2, huwiler2024seleniumsupplementationin pages 1-2) | HPO modifier: female predominance; epidemiology fields in KB | Kolanu 2024, DOI: 10.7759/cureus.54393; Durá-Travé 2024, DOI: 10.3390/ijms25063154; Huwiler 2024, DOI: 10.1089/thy.2023.0556 |
| Epidemiology | Age / natural history | Often insidious, chronic, and progressive; incidence rises after childhood and commonly presents in adolescents/adults, with hypothyroidism emerging over time (kolanu2024fromantibodiesto pages 1-2, duratrave2024autoimmunethyroiditisand pages 1-2) | HPO onset modifiers: adult onset / childhood onset variable | Kolanu 2024, DOI: 10.7759/cureus.54393; Durá-Travé 2024, DOI: 10.3390/ijms25063154 |
| Core diagnostic biomarkers | Thyroid autoantibodies | Anti-TPO (TPOAb) and anti-thyroglobulin (TgAb) are core serologic markers; seronegative disease occurs in about 5–10% of cases (kolanu2024fromantibodiesto pages 2-3, kolanu2024fromantibodiesto pages 1-2) | LOINC/SNOMED for TPOAb and TgAb; HPO: Positive circulating thyroid autoantibody level | Kolanu 2024, DOI: 10.7759/cureus.54393 |
| Core diagnostic biomarkers | Thyroid function tests | Typical biochemical pattern: elevated TSH with low FT4/FT3 in overt hypothyroid disease; TSH/FT4 central to diagnosis and follow-up (kolanu2024fromantibodiesto pages 2-3, huang2024traditionalchinesemedicine pages 4-5) | LOINC: TSH, free T4, free T3; HPO: Hypothyroidism, Abnormal thyroid-stimulating hormone level | Kolanu 2024, DOI: 10.7759/cureus.54393; Huang 2024, DOI: 10.3390/antiox13070868 |
| Core diagnostic biomarkers | Common symptoms / phenotype anchors | Frequent symptoms include fatigue, weight gain, cold intolerance, dry skin, constipation; reflect hypothyroid physiology rather than disease-specific autoimmunity (kolanu2024fromantibodiesto pages 2-3) | HPO: Fatigue, Weight gain, Cold intolerance, Dry skin, Constipation, Hypothyroidism | Kolanu 2024, DOI: 10.7759/cureus.54393 |
| Imaging / histopathology | Ultrasound | Typical ultrasonography: heterogeneous echotexture and diffuse hypoechogenicity; characteristic but not fully specific (kolanu2024fromantibodiesto pages 2-3, huwiler2024seleniumsupplementationin pages 1-2) | RadLex/SNOMED thyroid US findings; HPO: Abnormality of the thyroid gland | Kolanu 2024, DOI: 10.7759/cureus.54393; Huwiler 2024, DOI: 10.1089/thy.2023.0556 |
| Imaging / histopathology | Histopathology | Fine-needle aspiration / pathology may show dense lymphocytic infiltrates and germinal centers; thyroid tissue in HT contains T cells, B cells, macrophages around follicles (kolanu2024fromantibodiesto pages 2-3, martinezhernandez2024unravelingthemolecular pages 1-2) | GO: lymphocyte activation, germinal center formation; CL: T cell, B cell, macrophage | Kolanu 2024, DOI: 10.7759/cureus.54393; Martínez-Hernández 2024, DOI: 10.1038/s41467-024-50192-5 |
| Genetics | GWAS scale / susceptibility architecture | Large AITD GWAS meta-analysis included 110,945 cases and 1,084,290 controls and identified 290 variants at 225 loci, including 115 previously unreported; highlights T-cell regulatory genes outside MHC (saevarsdottir2024startcodonvariant pages 7-8) | GWAS Catalog entries; genes to prioritize: LAG3, ZAP70, HLA-region; disease inheritance: multifactorial/polygenic | Saevarsdottir 2024, DOI: 10.1038/s41467-024-50007-7 |
| Genetics | High-impact variant | Rare LAG3 5′UTR/start-codon variant rs781745126-T had the largest reported effect, OR 3.42, P = 2.2×10⁻¹⁶; carrier effect linked to reduced LAG-3 mRNA/surface expression and ~half plasma LAG-3 in heterozygotes; all 3 homozygotes had AITD (saevarsdottir2024startcodonvariant pages 7-8) | HGNC: LAG3; variant: rs781745126-T; GO: negative regulation of T cell activation | Saevarsdottir 2024, DOI: 10.1038/s41467-024-50007-7 |
| Genetics | Classic susceptibility genes | Reviews also cite HLA-DR and CTLA4 among established susceptibility factors in HT/AITD (kolanu2024fromantibodiesto pages 2-3) | HGNC: HLA-DR, CTLA4 | Kolanu 2024, DOI: 10.7759/cureus.54393 |
| Mechanisms / cell types | Core immune mechanism | HT is a T-cell-mediated autoimmune process with B-cell autoantibody production, thyroid lymphocytic infiltration, and progressive follicular injury leading to hypothyroidism (kolanu2024fromantibodiesto pages 2-3, duratrave2024autoimmunethyroiditisand pages 1-2) | GO: immune response, antigen processing and presentation, T cell activation; CL: CD4-positive T cell, B cell | Kolanu 2024, DOI: 10.7759/cureus.54393; Durá-Travé 2024, DOI: 10.3390/ijms25063154 |
| Mechanisms / cell types | Thyroid follicular cells / antigen presentation | Spatial transcriptomics identified damaged, de-differentiated thyroid follicular cells (TFCs) with increased CD74 and MIF expression, consistent with aberrant MHC-II antigen presentation and a CD74/MIF autocrine loop promoting immune recruitment/repair signaling (martinezhernandez2024unravelingthemolecular pages 12-13, martinezhernandez2024unravelingthemolecular pages 1-2, martinezhernandez2024unravelingthemolecular pages 13-14) | CL: thyroid follicular cell; GO: antigen processing and presentation of peptide antigen via MHC class II, response to interferon-gamma | Martínez-Hernández 2024, DOI: 10.1038/s41467-024-50192-5 |
| Mechanisms / cell types | Immune infiltrates | HT tissue showed rich infiltrates with T cells, B lymphocytes, inflammatory macrophages, and myeloid cells; T-cell genes (TRAC, TRBC1, CD3D) and B-cell markers (MS4A1, CR2) were enriched in infiltrated zones (martinezhernandez2024unravelingthemolecular pages 1-2, martinezhernandez2024unravelingthemolecular pages 9-12) | CL: T cell, B cell, macrophage, dendritic cell; GO: lymphocyte chemotaxis | Martínez-Hernández 2024, DOI: 10.1038/s41467-024-50192-5 |
| Mechanisms / cell types | Fibroblast subtypes | Two fibroblast programs were emphasized: inflammatory-associated fibroblasts, including CXCL12+ and IGFBP6+ populations linked to immune chemotaxis/ECM remodeling, and myofibroblast-like populations in interfollicular areas (martinezhernandez2024unravelingthemolecular pages 12-13, martinezhernandez2024unravelingthemolecular pages 13-14) | CL: fibroblast, myofibroblast; GO: extracellular matrix organization, chemokine-mediated signaling pathway | Martínez-Hernández 2024, DOI: 10.1038/s41467-024-50192-5 |
| Mechanisms / cell types | Endothelial / vascular changes | Spatial data showed increased vascular permeability and specialized endothelial structures, including ACKR1+ high endothelial venules in HT infiltrates; broader AITD work also noted PLVAP+ fenestrated vessels (martinezhernandez2024unravelingthemolecular pages 9-12, martinezhernandez2024unravelingthemolecular pages 13-14) | CL: endothelial cell; GO: angiogenesis, regulation of vascular permeability; UBERON: thyroid vasculature | Martínez-Hernández 2024, DOI: 10.1038/s41467-024-50192-5 |
| Mechanisms / cell types | Cytokine context | IFN-γ and TNF-α upregulate CD74 in TFCs and infiltrating immune cells, amplifying receptor-ligand interactions and antigen-presentation signaling (martinezhernandez2024unravelingthemolecular pages 12-13, martinezhernandez2024unravelingthemolecular pages 9-12) | CHEBI: interferon gamma, tumor necrosis factor alpha; GO: cellular response to interferon-gamma, inflammatory response | Martínez-Hernández 2024, DOI: 10.1038/s41467-024-50192-5 |
| Environmental / risk factors | Environment and micronutrients | Reviews cite environmental triggers including excess dietary iodine and possible toxicant exposures; vitamin D deficiency is repeatedly associated with HT, though causality/intervention evidence remains incomplete (kolanu2024fromantibodiesto pages 2-3, duratrave2024autoimmunethyroiditisand pages 1-2) | CHEBI: iodine, cholecalciferol; exposure ontology terms as available | Kolanu 2024, DOI: 10.7759/cureus.54393; Durá-Travé 2024, DOI: 10.3390/ijms25063154 |
| Standard treatment | Levothyroxine replacement | Standard of care for overt hypothyroidism due to HT is lifelong oral levothyroxine (LT4) to normalize TSH; therapy addresses hormone deficiency but not the upstream autoimmune process, inflammation, or oxidative stress (huwiler2024seleniumsupplementationin pages 1-2, huang2024traditionalchinesemedicine pages 4-5) | MAXO: thyroid hormone replacement therapy, administration of levothyroxine; CHEBI: levothyroxine | Huwiler 2024, DOI: 10.1089/thy.2023.0556; Huang 2024, DOI: 10.3390/antiox13070868 |
| Adjunct / disease-modifying | Selenium meta-analysis | 2024 systematic review/meta-analysis of 35 studies found selenium lowered TSH in patients without thyroid hormone replacement (SMD −0.21, 95% CI −0.43 to −0.02; 7 cohorts, n=869), lowered TPOAb (SMD −0.96, 95% CI −1.36 to −0.56; 29 cohorts, n=2,358), lowered MDA (SMD −1.16; 3 cohorts, n=248), with adverse events similar to control (OR 0.89, 95% CI 0.46–1.75; 16 cohorts, n=1,339) (huwiler2024seleniumsupplementationin pages 1-2, huwiler2024seleniumsupplementationin pages 8-9, huwiler2024seleniumsupplementationin pages 11-12) | MAXO: selenium supplementation; CHEBI: selenium, selenium-enriched yeast | Huwiler 2024, DOI: 10.1089/thy.2023.0556 |
| Adjunct / disease-modifying | Selenium QoL RCT | CATALYST RCT: 412 patients with autoimmune thyroiditis on LT4, 332 (81%) completed 12 months; 200 μg/day selenium vs placebo improved QoL similarly in both groups with no between-group difference in ThyPRO-39 composite score (28.8 vs 28.0, P=0.602). TPOAb was lower with selenium after 12 months (1995 vs 2344 kIU/L, P=0.016); no meaningful TSH difference (P=0.688) and no serious safety signal (larsen2024seleniumsupplementationand pages 1-2, larsen2024seleniumsupplementationand pages 6-8, larsen2024seleniumsupplementationand pages 8-10) | MAXO: selenium supplementation, patient-reported outcome assessment | Larsen 2024, DOI: 10.1530/etj-23-0175 |
| Adjunct / disease-modifying | Vitamin D | Review-level evidence: HT patients often have lower vitamin D levels; some studies show reduced thyroid autoantibody titers after cholecalciferol in vitamin D-deficient HT, but authors stress need for more randomized double-blind placebo-controlled trials (duratrave2024autoimmunethyroiditisand pages 1-2) | MAXO: vitamin D supplementation; CHEBI: cholecalciferol | Durá-Travé 2024, DOI: 10.3390/ijms25063154 |
| Experimental / ongoing trials | Vitamin D adjuvant trial | NCT05871957: prospective observational cohort; 30 female participants (18–60 years) with HT and hypothyroidism; vitamin D drops 2000 IU/day for 1 month; primary outcome TPOAb, secondary TgAb, FT3, FT4, TSH; status in registry chunk: not yet recruiting (NCT05871957 chunk 1, NCT05871957 chunk 2) | NCT: NCT05871957; MAXO: vitamin D supplementation | ClinicalTrials.gov, NCT05871957 |
| Experimental / ongoing trials | Hydroxychloroquine trial | NCT01760421: completed single-group interventional study; 40 euthyroid adults; hydroxychloroquine 200 mg twice daily for 6 months; primary outcomes anti-TPO and anti-thyroglobulin; secondary outcomes included elastography, FT4/TSH, and inflammatory cytokines (IL-1, IL-6, TNF-α) (NCT01760421 chunk 1) | NCT: NCT01760421; MAXO: hydroxychloroquine therapy | ClinicalTrials.gov, NCT01760421 |
| Experimental / ongoing trials | Dietary intervention trial | NCT05949671: interventional diet study in women with confirmed HT; total registry search reported 40 participants; compares gluten-free and Mediterranean diet approaches over 12 weeks with personalized dietitian support; primary focus is effect on the autoimmune system (NCT05949671 chunk 2) | NCT: NCT05949671; MAXO: dietary modification, gluten-free diet, Mediterranean diet | ClinicalTrials.gov, NCT05949671 |
| Experimental / ongoing trials | Photobiomodulation trial | NCT06735040: interventional study in HT patients on LT4; registry search reported 60 participants; outcomes over about 3 months included depression, anxiety, and fatigue measures, reflecting symptom-focused adjunctive management (NCT06735040 chunk 2) | NCT: NCT06735040; MAXO: photobiomodulation therapy | ClinicalTrials.gov, NCT06735040 |
| Visual / reference resource | Mechanistic figure | Figure 8 from the 2024 spatial transcriptomics study provides a concise mechanistic map of HT: damaged CD74-high TFCs, CD74/MIF loop, inflammatory fibroblasts, endothelial remodeling, and immune infiltration (martinezhernandez2024unravelingthemolecular media c4e4de12, martinezhernandez2024unravelingthemolecular media b04d5261) | Evidence figure linkable in KB; GO/CL mapping support | Martínez-Hernández 2024, DOI: 10.1038/s41467-024-50192-5 |
Table: This table summarizes high-yield disease-characteristic facts for a Hashimoto’s thyroiditis knowledge-base entry, emphasizing 2023–2024 evidence, ontology suggestions, quantitative findings, and trial identifiers.
URLs, publication dates, and authority notes (key 2024 sources used)
- Martínez-Hernández et al., Nature Communications, July 2024. Spatial transcriptomics of AITD at tissue resolution. https://doi.org/10.1038/s41467-024-50192-5 (martinezhernandez2024unravelingthemolecular pages 1-2)
- Saevarsdottir et al., Nature Communications, July 2024. AITD GWAS meta-analysis + functional multiomics; LAG3 variant. https://doi.org/10.1038/s41467-024-50007-7 (saevarsdottir2024startcodonvariant pages 7-8)
- Huwiler et al., Thyroid, March 2024. Selenium systematic review/meta-analysis. https://doi.org/10.1089/thy.2023.0556 (huwiler2024seleniumsupplementationin pages 1-2)
- Larsen et al., European Thyroid Journal, January 2024. Selenium RCT (CATALYST) in autoimmune thyroiditis on LT4. https://doi.org/10.1530/etj-23-0175 (larsen2024seleniumsupplementationand pages 1-2)
- Durá-Travé & Gallinas-Victoriano, International Journal of Molecular Sciences, March 2024. Vitamin D and autoimmune thyroiditis. https://doi.org/10.3390/ijms25063154 (duratrave2024autoimmunethyroiditisand pages 1-2)
- Kolanu et al., Cureus, February 2024. Diagnostic challenges and emerging AI. https://doi.org/10.7759/cureus.54393 (kolanu2024fromantibodiesto pages 2-3)
- ClinicalTrials.gov entries: NCT05871957; NCT01760421; NCT05949671; NCT06735040. (NCT05871957 chunk 1, NCT01760421 chunk 1, NCT05949671 chunk 2, NCT06735040 chunk 2)
References
-
(huwiler2024seleniumsupplementationin pages 1-2): Valentina V. Huwiler, Stephanie Maissen-Abgottspon, Zeno Stanga, Stefan Mühlebach, Roman Trepp, Lia Bally, and Arjola Bano. Selenium supplementation in patients with hashimoto thyroiditis: a systematic review and meta-analysis of randomized clinical trials. Mar 2024. URL: https://doi.org/10.1089/thy.2023.0556, doi:10.1089/thy.2023.0556. This article has 132 citations.
-
(kolanu2024fromantibodiesto pages 2-3): Nikhil Deep Kolanu, Naimel Ansar Awan, Ayesha Imran Butt, Taufiqa Reza, Mohammed Khaleel I.KH. Almadhoun, Taher Janoowala, Syed Faqeer Hussain Bokhari, Zukhruf Zain, Tanzila Sharif, Lokesh Chauhan, and Jinal Choudhari. From antibodies to artificial intelligence: a comprehensive review of diagnostic challenges in hashimoto’s thyroiditis. Cureus, Feb 2024. URL: https://doi.org/10.7759/cureus.54393, doi:10.7759/cureus.54393. This article has 19 citations.
-
(saevarsdottir2024startcodonvariant pages 7-8): Saedis Saevarsdottir, Kristbjörg Bjarnadottir, Thorsteinn Markusson, Jonas Berglund, Thorunn A. Olafsdottir, Gisli H. Halldorsson, Gudrun Rutsdottir, Kristbjorg Gunnarsdottir, Asgeir Orn Arnthorsson, Sigrun H. Lund, Lilja Stefansdottir, Julius Gudmundsson, Ari J. Johannesson, Arni Sturluson, Asmundur Oddsson, Bjarni Halldorsson, Björn R. Ludviksson, Egil Ferkingstad, Erna V. Ivarsdottir, Gardar Sveinbjornsson, Gerdur Grondal, Gisli Masson, Grimur Hjorleifsson Eldjarn, Gudmundur A. Thorisson, Katla Kristjansdottir, Kirk U. Knowlton, Kristjan H. S. Moore, Sigurjon A. Gudjonsson, Solvi Rognvaldsson, Stacey Knight, Lincoln D. Nadauld, Hilma Holm, Olafur T. Magnusson, Patrick Sulem, Daniel F. Gudbjartsson, Thorunn Rafnar, Gudmar Thorleifsson, Pall Melsted, Gudmundur L. Norddahl, Ingileif Jonsdottir, and Kari Stefansson. Start codon variant in lag3 is associated with decreased lag-3 expression and increased risk of autoimmune thyroid disease. Nature Communications, Jul 2024. URL: https://doi.org/10.1038/s41467-024-50007-7, doi:10.1038/s41467-024-50007-7. This article has 14 citations and is from a highest quality peer-reviewed journal.
-
(martinezhernandez2024unravelingthemolecular pages 1-2): Rebeca Martínez-Hernández, Nuria Sánchez de la Blanca, Pablo Sacristán-Gómez, Ana Serrano-Somavilla, José Luis Muñoz De Nova, Fátima Sánchez Cabo, Holger Heyn, Miguel Sampedro-Núñez, and Mónica Marazuela. Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution. Nature Communications, Jul 2024. URL: https://doi.org/10.1038/s41467-024-50192-5, doi:10.1038/s41467-024-50192-5. This article has 35 citations and is from a highest quality peer-reviewed journal.
-
(martinezhernandez2024unravelingthemolecular pages 9-12): Rebeca Martínez-Hernández, Nuria Sánchez de la Blanca, Pablo Sacristán-Gómez, Ana Serrano-Somavilla, José Luis Muñoz De Nova, Fátima Sánchez Cabo, Holger Heyn, Miguel Sampedro-Núñez, and Mónica Marazuela. Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution. Nature Communications, Jul 2024. URL: https://doi.org/10.1038/s41467-024-50192-5, doi:10.1038/s41467-024-50192-5. This article has 35 citations and is from a highest quality peer-reviewed journal.
-
(martinezhernandez2024unravelingthemolecular pages 13-14): Rebeca Martínez-Hernández, Nuria Sánchez de la Blanca, Pablo Sacristán-Gómez, Ana Serrano-Somavilla, José Luis Muñoz De Nova, Fátima Sánchez Cabo, Holger Heyn, Miguel Sampedro-Núñez, and Mónica Marazuela. Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution. Nature Communications, Jul 2024. URL: https://doi.org/10.1038/s41467-024-50192-5, doi:10.1038/s41467-024-50192-5. This article has 35 citations and is from a highest quality peer-reviewed journal.
-
(kolanu2024fromantibodiesto pages 1-2): Nikhil Deep Kolanu, Naimel Ansar Awan, Ayesha Imran Butt, Taufiqa Reza, Mohammed Khaleel I.KH. Almadhoun, Taher Janoowala, Syed Faqeer Hussain Bokhari, Zukhruf Zain, Tanzila Sharif, Lokesh Chauhan, and Jinal Choudhari. From antibodies to artificial intelligence: a comprehensive review of diagnostic challenges in hashimoto’s thyroiditis. Cureus, Feb 2024. URL: https://doi.org/10.7759/cureus.54393, doi:10.7759/cureus.54393. This article has 19 citations.
-
(NCT05871957 chunk 1): Adjuvant Therapeutic Effect of Vitamin D on Hashimoto's Thyroiditis. Qianfoshan Hospital. 2023. ClinicalTrials.gov Identifier: NCT05871957
-
(duratrave2024autoimmunethyroiditisand pages 1-2): Teodoro Durá-Travé and Fidel Gallinas-Victoriano. Autoimmune thyroiditis and vitamin d. International Journal of Molecular Sciences, 25:3154, Mar 2024. URL: https://doi.org/10.3390/ijms25063154, doi:10.3390/ijms25063154. This article has 78 citations.
-
(huang2024traditionalchinesemedicine pages 4-5): Sheng Huang, Panos G. Ziros, Dionysios V. Chartoumpekis, Georgios Psarias, Leonidas Duntas, Xinhe Zuo, Xinyi Li, Zhiguo Ding, and Gerasimos P. Sykiotis. Traditional chinese medicine for hashimoto’s thyroiditis: focus on selenium and antioxidant phytochemicals. Antioxidants, 13:868, Jul 2024. URL: https://doi.org/10.3390/antiox13070868, doi:10.3390/antiox13070868. This article has 14 citations.
-
(martinezhernandez2024unravelingthemolecular pages 12-13): Rebeca Martínez-Hernández, Nuria Sánchez de la Blanca, Pablo Sacristán-Gómez, Ana Serrano-Somavilla, José Luis Muñoz De Nova, Fátima Sánchez Cabo, Holger Heyn, Miguel Sampedro-Núñez, and Mónica Marazuela. Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution. Nature Communications, Jul 2024. URL: https://doi.org/10.1038/s41467-024-50192-5, doi:10.1038/s41467-024-50192-5. This article has 35 citations and is from a highest quality peer-reviewed journal.
-
(martinezhernandez2024unravelingthemolecular media c4e4de12): Rebeca Martínez-Hernández, Nuria Sánchez de la Blanca, Pablo Sacristán-Gómez, Ana Serrano-Somavilla, José Luis Muñoz De Nova, Fátima Sánchez Cabo, Holger Heyn, Miguel Sampedro-Núñez, and Mónica Marazuela. Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution. Nature Communications, Jul 2024. URL: https://doi.org/10.1038/s41467-024-50192-5, doi:10.1038/s41467-024-50192-5. This article has 35 citations and is from a highest quality peer-reviewed journal.
-
(martinezhernandez2024unravelingthemolecular media b04d5261): Rebeca Martínez-Hernández, Nuria Sánchez de la Blanca, Pablo Sacristán-Gómez, Ana Serrano-Somavilla, José Luis Muñoz De Nova, Fátima Sánchez Cabo, Holger Heyn, Miguel Sampedro-Núñez, and Mónica Marazuela. Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution. Nature Communications, Jul 2024. URL: https://doi.org/10.1038/s41467-024-50192-5, doi:10.1038/s41467-024-50192-5. This article has 35 citations and is from a highest quality peer-reviewed journal.
-
(kolanu2024fromantibodiesto pages 5-6): Nikhil Deep Kolanu, Naimel Ansar Awan, Ayesha Imran Butt, Taufiqa Reza, Mohammed Khaleel I.KH. Almadhoun, Taher Janoowala, Syed Faqeer Hussain Bokhari, Zukhruf Zain, Tanzila Sharif, Lokesh Chauhan, and Jinal Choudhari. From antibodies to artificial intelligence: a comprehensive review of diagnostic challenges in hashimoto’s thyroiditis. Cureus, Feb 2024. URL: https://doi.org/10.7759/cureus.54393, doi:10.7759/cureus.54393. This article has 19 citations.
-
(larsen2024seleniumsupplementationand pages 1-2): Camilla Bøgelund Larsen, Kristian Hillert Winther, Per Karkov Cramon, Åse Krogh Rasmussen, Ulla Feldt-Rasmussen, Nils Jakob Knudsen, Jakob Bue Bjorner, Lutz Schomburg, Kamil Demircan, Thilo Samson Chillon, Jeppe Gram, Stinus Gadegaard Hansen, Frans Brandt, Birte Nygaard, Torquil Watt, Laszlo Hegedüs, and Steen Joop Bonnema. Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism. European Thyroid Journal, Jan 2024. URL: https://doi.org/10.1530/etj-23-0175, doi:10.1530/etj-23-0175. This article has 40 citations and is from a peer-reviewed journal.
-
(NCT01760421 chunk 1): The Effect of Hydroxychloroquine Treatment in Hashimoto's Thyroiditis. National Taiwan University Hospital. 2011. ClinicalTrials.gov Identifier: NCT01760421
-
(NCT05949671 chunk 2): Evaluation of the Effect of Gluten-Free Diet and Mediterranean Diet. Acibadem University. 2021. ClinicalTrials.gov Identifier: NCT05949671
-
(NCT06735040 chunk 2): Sümeyye TUNÇ. Effect of Photobiomodulation Therapy in Patients With Hashimoto's Thyroiditis. Istanbul Medipol University Hospital. 2021. ClinicalTrials.gov Identifier: NCT06735040
-
(huwiler2024seleniumsupplementationin pages 8-9): Valentina V. Huwiler, Stephanie Maissen-Abgottspon, Zeno Stanga, Stefan Mühlebach, Roman Trepp, Lia Bally, and Arjola Bano. Selenium supplementation in patients with hashimoto thyroiditis: a systematic review and meta-analysis of randomized clinical trials. Mar 2024. URL: https://doi.org/10.1089/thy.2023.0556, doi:10.1089/thy.2023.0556. This article has 132 citations.
-
(huwiler2024seleniumsupplementationin pages 11-12): Valentina V. Huwiler, Stephanie Maissen-Abgottspon, Zeno Stanga, Stefan Mühlebach, Roman Trepp, Lia Bally, and Arjola Bano. Selenium supplementation in patients with hashimoto thyroiditis: a systematic review and meta-analysis of randomized clinical trials. Mar 2024. URL: https://doi.org/10.1089/thy.2023.0556, doi:10.1089/thy.2023.0556. This article has 132 citations.
-
(larsen2024seleniumsupplementationand pages 6-8): Camilla Bøgelund Larsen, Kristian Hillert Winther, Per Karkov Cramon, Åse Krogh Rasmussen, Ulla Feldt-Rasmussen, Nils Jakob Knudsen, Jakob Bue Bjorner, Lutz Schomburg, Kamil Demircan, Thilo Samson Chillon, Jeppe Gram, Stinus Gadegaard Hansen, Frans Brandt, Birte Nygaard, Torquil Watt, Laszlo Hegedüs, and Steen Joop Bonnema. Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism. European Thyroid Journal, Jan 2024. URL: https://doi.org/10.1530/etj-23-0175, doi:10.1530/etj-23-0175. This article has 40 citations and is from a peer-reviewed journal.
-
(larsen2024seleniumsupplementationand pages 8-10): Camilla Bøgelund Larsen, Kristian Hillert Winther, Per Karkov Cramon, Åse Krogh Rasmussen, Ulla Feldt-Rasmussen, Nils Jakob Knudsen, Jakob Bue Bjorner, Lutz Schomburg, Kamil Demircan, Thilo Samson Chillon, Jeppe Gram, Stinus Gadegaard Hansen, Frans Brandt, Birte Nygaard, Torquil Watt, Laszlo Hegedüs, and Steen Joop Bonnema. Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism. European Thyroid Journal, Jan 2024. URL: https://doi.org/10.1530/etj-23-0175, doi:10.1530/etj-23-0175. This article has 40 citations and is from a peer-reviewed journal.
-
(NCT05871957 chunk 2): Adjuvant Therapeutic Effect of Vitamin D on Hashimoto's Thyroiditis. Qianfoshan Hospital. 2023. ClinicalTrials.gov Identifier: NCT05871957